1	IN THE SUPREME COURT OF THE UNITED STATES
2	x
3	POM WONDERFUL LLC, :
4	Petitioner : No. 12-761
5	v. :
6	THE COCA-COLA COMPANY. :
7	x
8	Washington, D.C.
9	Monday, April 21, 2014
10	
11	The above-entitled matter came on for oral
12	argument before the Supreme Court of the United States
13	at 11:06 a.m.
14	APPEARANCES:
15	SETH P. WAXMAN, ESQ., Washington, D.C.; on behalf of
16	Petitioner.
17	MELISSA ARBUS SHERRY, ESQ., Assistant to the Solicitor
18	General, Department of Justice, Washington, D.C.; on
19	behalf of United States, as amicus curiae, supporting
20	neither party.
21	KATHLEEN M. SULLIVAN, ESQ., New York, New York; on
22	behalf of Respondent.
23	
24	
25	

1	CONTENTS	
2	ORAL ARGUMENT OF	PAGE
3	SETH P. WAXMAN, ESQ.	
4	On behalf of the Petitioner	3
5	ORAL ARGUMENT OF	
6	MELISSA ARBUS SHERRY, ESQ.	
7	On behalf of United States, as amicus	
8	curiae, supporting neither party	15
9	ORAL ARGUMENT OF	
10	KATHLEEN M. SULLIVAN, ESQ.	
11	On behalf of the Respondent	25
12	REBUTTAL ARGUMENT OF	
13	SETH P. WAXMAN, ESQ.	
14	On behalf of the Petitioner	46
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

1	PROCEEDINGS
2	(11:06 a.m.)
3	CHIEF JUSTICE ROBERTS: We'll hear argument
4	next in Case No. 12-761, POM Wonderful v. The Coca-Cola
5	Company.
6	Mr. Waxman?
7	ORAL ARGUMENT OF SETH P. WAXMAN
8	ON BEHALF OF THE PETITIONER
9	MR. WAXMAN: Mr. Chief Justice, and may it
10	please the Court:
11	The Lanham Act provides a remedy for
12	businesses whose market is misappropriated by
13	competitors that misrepresent the character of the goods
14	they sell. This case presents an egregious violation of
15	the law. Coca-Cola's label grossly misleads consumers,
16	as Coke anticipated, but Coke says that it need not
17	answer under the Lanham Act because its label is
18	authorized by FDA regulations. The label is not, in
19	fact, authorized for reasons we explain and with which
20	the United States largely agrees, but even if it were
21	consistent with FDA regulations that would not strip POM
22	of its right to prove a willful Lanham Act violation.
23	Courts are obligated to give full effect to
24	Congressional enactments wherever possible. Here
25	Congress has never precluded or conditioned enforcement

- 1 of the Lanham Act in food labeling cases, and it is
- 2 entirely possible, in fact, entirely easy for Coke to
- 3 comply with both statutory obligations.
- 4 JUSTICE SOTOMAYOR: If there is no private
- 5 cause of action to enforce the FDA label standards, only
- 6 the FDA can bring a proceeding to say that an ad
- 7 violates its regulations, how does a Court below,
- 8 without interpreting the regulations, go about deciding
- 9 whether or not a particular ad doesn't comport with the
- 10 regulations and hence would be subject to the Lanham
- 11 Act?
- 12 MR. WAXMAN: Justice --
- JUSTICE SOTOMAYOR: Maybe that's a better
- 14 question for the SG, but I'm trying to figure out --
- 15 MR. WAXMAN: Well, let me take a shot at it
- 16 and, you know, the SG can and Ms. Sullivan can, as well.
- 17 There's no question under -- as this Court
- 18 explained in Buckman, that there is no private cause of
- 19 action to enforce provisions of the FDCA. Now, this
- 20 Court in Buckman distinguished Medtronic v. Lohr, which
- 21 provided and held -- and did not and save from preemption a
- 22 state law that was- that imposed parallel requirements, and in
- 23 that instance, and this is not a case involving an
- 24 attempt to enforce parallel requirements under state law
- 25 or any other law. In those circumstances, as the

- 1 government explains, of course a court is going to be
- 2 required to ascertain what those parallel requirements
- 3 are, and whether they were or weren't complied with.
- 4 But this is a case involving a different
- 5 statute. Our submission is that it is entirely
- 6 irrelevant whether or not the Coke label, in any
- 7 particular, is consistent with a regulation that
- 8 implements criminal prohibitions by announcing when and
- 9 under what limited circumstances the FDA will forebear
- 10 from exercising its criminal and regulatory penalties.
- 11 Even in that instance, with respect, Your Honor, as this
- 12 Court explained in Wyeth, misbranding provisions are, in
- 13 fact, adjudicated by courts even under the FDCA.
- 14 JUSTICE KENNEDY: And so do you concede that
- 15 under the Lanham Act, plaintiff could not challenge
- 16 aspects of the a food label that the FDA said is
- 17 required?
- 18 MR. WAXMAN: Well, Justice Kennedy --
- 19 JUSTICE KENNEDY: I know that's not this
- 20 case.
- MR. WAXMAN: Thank you.
- Let me just say, not only is that not this
- 23 case because the FDA has never examined --
- 24 JUSTICE KENNEDY: I want you to answer the
- 25 question, though.

- 1 MR. WAXMAN: My answer to the question would
- 2 be, under Wyeth, under this Court's decision in Wyeth,
- 3 the FDCA and the FDA's regulations interpreting it and
- 4 applying it, supply a floor and not a ceiling. And the
- 5 FDA would have no authority -- if the FDA said, This
- 6 label is fine and you are required to use this label,
- 7 the question would be, does it have the statutory
- 8 authority to essentially create an immunity from
- 9 enforcement of another federal statute that protects a
- 10 different purpose and a different class of victims? The
- 11 answer would be no.
- 12 JUSTICE KAGAN: Justice Kennedy's question,
- 13 I think, was different. He said, suppose that it said
- 14 you are required to use this label and only this label,
- 15 then you would acknowledge that there is an
- 16 impossibility issue; is that right?
- 17 MR. WAXMAN: Yes. Unless, as in Wyeth,
- 18 there was, in fact, some possibility to change the
- 19 label, but if -- and I apologize if I didn't understand
- 20 the question. If the FDA said, counterfactually, we've
- 21 examined this label, you are not only permitted to use
- 22 it but you are required to use it, and unlike what we do
- 23 with respect to pharmaceuticals, you are not allowed to
- 24 make any changes. In that instance, there would be an
- 25 irreconcilable conflict and a Court would have to decide

- 1 which of two opposite-facing canons of construction to
- 2 give primacy to, but that would be impossibility.
- 3 JUSTICE KAGAN: Why isn't there a different
- 4 kind of conflict here? Let's just focus on the name,
- 5 which is what the solicitor general says the FDA has
- 6 considered and has specifically permitted. They went
- 7 through this very long and involved process, and they
- 8 decided exactly what kind of names were permitted for
- 9 this kind of product and what were not permitted,
- 10 because they constituted misbranding. And essentially
- 11 the FDA has said, This is what counts as misbranding,
- 12 nothing else counts as misbranding. And now you're
- 13 coming in and under a Lanham Act claim saying, no, the
- 14 FDA is wrong. This is misbranding. That seems -- why
- isn't that a problem?
- 16 MR. WAXMAN: Why isn't that a problem?
- 17 JUSTICE KAGAN: Yeah. That the FDA said
- 18 it's not misbranding, you're saying it is misbranding.
- 19 That seems a quite direct conflict as to what the FDA
- 20 says versus what you are alleging under the Lanham Act.
- 21 MR. WAXMAN: So we know that that is not, in
- 22 fact, how the FDA construes its regulation, and we know
- 23 that because just by examining the FDA's own limited
- 24 enforcement history, all the parties have cited the
- 25 Court --

- 1 JUSTICE KAGAN: Well, just hypothetically,
- 2 let's say that the FDA said that this name was not
- 3 misbranding, that this name was fine under their
- 4 regulations, that they did not count as misbranding.
- 5 MR. WAXMAN: So we're challenging the label
- 6 as a whole, which is covered by -- under the --
- 7 JUSTICE KAGAN: Right. So I understand
- 8 that, you would have some claims about different parts
- 9 of the label. But I'm only asking about your
- 10 claiming as -- your claim as to the specific thing that
- 11 the FDA ruled on.
- 12 MR. WAXMAN: Right. And the question is
- 13 whether Congress gave any indication and it would have
- 14 to, in this context where the Lanham Act is an express
- 15 statutory enactment that Congress was well aware of when
- 16 it enacted the Nutrition Labeling Act and, in fact, was
- 17 told, not just by the industry, but by OMB, in
- 18 testimony, that the Lanham Act was being used to police
- 19 misrepresentations of the character of food products,
- 20 you would have to conclude that Congress intended to
- 21 allow the FDA to supply, if you will, the substantive
- 22 rule of decision under a different statute that uses
- 23 different words and -- and protects a different class of
- 24 people when -- and here again, I think it's an important
- 25 indicator why Congress didn't mean that. The FDA, the

- 1 misbranding provisions of the FDCA are prohibitions.
- 2 They are not permissions. And the rules that the FDA
- 3 has promulgated announce essentially an enforcement
- 4 forbearance. They don't represent a judgment and the
- 5 Federal Register provisions that we've cited that
- 6 accompanied the promulgation of the juice naming
- 7 regulations make this as clear as day. They do not
- 8 represent a pronouncement that for all purposes, for all
- 9 statutes, the name on -- the name ascribed to the
- 10 product is okay. In fact, they say although for
- 11 purposes of our forbearance under our government
- 12 enforcement authority, we will allow you to do one or
- 13 the other -- and this is 2919 and 2920 of Federal
- 14 Register 58, We warn manufacturers that even compliance
- 15 with this, where there is a small amount of the
- 16 non-predominant juice name has great capacity to mislead
- 17 and we encourage -- twice in the rulemaking, we
- 18 encourage manufacturers, nonetheless, to name the juices
- 19 in the product. Under those circumstances, the notion
- 20 that Congress intended this type of regulation to
- 21 preclude a case in which -- and these are the facts as
- 22 the Court -- as they come to the Court -- Coke well knew
- 23 and intentionally designed a label that, in fact,
- 24 grossly misleads consumers to the economic disadvantage
- of the company that, in large part, created the market.

- 1 And the notion that Congress wanted to allow the FDA to
- 2 apply substantive rules of decision in that very
- 3 different inquiry using very different language in a
- 4 different statute, I think, is completely unsupported.
- 5 I mean --
- 6 JUSTICE GINSBURG: What would be the
- 7 components of the injunctive relief that you would seek?
- 8 Assuming you have a Lanham Act claim, what should Coke
- 9 have done to make its product non-misleading?
- 10 MR. WAXMAN: Well, we have in -- in the
- 11 course of our complaint, we didn't specify -- I mean,
- 12 the injunction that we would seek is ceasing to use the
- 13 label as it currently exists, and of course --
- 14 JUSTICE GINSBURG: Without saying what label
- 15 would be lawful?
- 16 MR. WAXMAN: That's correct. It's just as
- 17 in criminal actions under the FDCA and civil actions
- 18 under parallel state laws and actions under the Lanham
- 19 Act, juries aren't required or permitted to give
- 20 prescriptive judgments. All that they may -- all they
- 21 do is make a judgment about whether or not on balance,
- 22 there is substantial evidence that to the harm of the
- 23 competitor, a substantial number of consumers are
- 24 misled, and if so, was it willful. And that is no more
- 25 of a problem in this particular case than it is in any

- of these cases, whether they involve food or anything
- 2 else. In Wyeth versus Levine, the plaintiff had all
- 3 sorts of reasons -- all sorts of different theories
- 4 about what the warning label should or shouldn't say.
- 5 The jury simply decided that it violated the common law
- of the state of Vermont to use that particular label.
- 7 And the FD -- I'm sorry.
- 8 JUSTICE ALITO: Suppose the percentage were
- 9 a lot higher. Suppose it was 50 percent pomegranate and
- 10 blueberry.
- 11 MR. WAXMAN: It's hard to see how we
- 12 would have a -- it's hard to see how we would have a --
- 13 could possibly prevail in a Lanham Act case. I mean, we
- 14 have to come up with -- we have to adduce, it's our
- 15 burden, substantial evidence to show that a substantial
- 16 number of competitors -- of consumers are not only
- 17 misled, but misled to the detriment of our product. I
- 18 don't think we could establish it. But Coke's argument,
- 19 and for that matter the government's argument, with
- 20 respect to the name itself, would apply if, unlike the
- 21 eyedropper's worth of pomegranate juice that's in the
- 22 half-gallon bottle, there were two microns. I mean,
- 23 this -- the question simply is whether a manufacturer
- 24 like Coca-Cola can design something that it knows runs a
- 25 substantial risk, quote, "from a misleading

- 1 perspective." And the evidence shows that over a third
- 2 of consumers who look at this label believe that
- 3 pomegranate and blueberry juice, in fact, are the
- 4 majority juices.
- 5 JUSTICE ALITO: What if it were the -- what
- 6 if it were the case that there were very small number of
- 7 people who were allergic to one of these ingredients?
- 8 I'm not suggesting it's true. For all I know, it's not.
- 9 But let's say there are a few people who are very
- 10 allergic to pomegranate juice or blueberry juice. And
- 11 so the FDA says, if you put even an eyedropper full of
- 12 that in your blend, you have to put that prominently on
- 13 the bottle so that these people will not inadvertently
- 14 get an allergic reaction. Could you have a Lanham Act
- 15 claim then?
- MR. WAXMAN: Well, of course, pome -- the
- 17 only thing that consumers know is that -- from the front
- 18 label is that there is pomegranate -- arguably
- 19 pomegranate juice and blueberry juice in here. So the
- 20 question would be whether they had to disclose on the
- 21 label whether there was also .01 percent strawberry
- juice or 99.4 percent apple and grape juice. That's the
- 23 kind of judgment that we want the FDA to make, because
- 24 the purpose of the FDCA is protect public health and
- 25 safety.

1 What the FDA doesn't do, particularly given 2 the criminal nature of its sanctions, is regulate or 3 interpret, apply its forbearance authority with an eye 4 toward, well, what kinds of things are going to so 5 mislead consumers that they think there is going to be a 6 substitute in the marketplace where there isn't. 7 Well, what I'm saying is JUSTICE ALITO: suppose it's the case that for 99.999 percent of the 8 9 population, the more pomegranate juice, the better, you 10 just can't drink enough of it. The more you drink, the 11 healthier you are. But for this tiny percentage of the 12 population, it could produce an allergic reaction. And 13 so the FDA says, you've got to put that on there even if 14 there is just a tincture of pomegranate juice. Could 15 you have a Lanham Act claim on the ground for the vast 16 majority of your potential customers, they are going to 17 be misled, because they want pomegranate juice and they 18 are buying this stuff that just has a little bit of it 19 in it? 20 MR. WAXMAN: Well, I think the vast --21 presumably, and we're talking about a hypothetical 22 regulation, presumably the FDA would promulgate a 23 requirement that, in fact, you must name each of the --

allergy. I mean, we wouldn't have an objection -- the

each of the constituent juices in case there is an

24

25

- 1 argument wouldn't be that consumers are misled by that
- 2 fact alone. What's misleading consumers here is they
- 3 have no way on God's green earth of telling that the
- 4 total amount of blueberry and pomegranate juice in this
- 5 product can be dispensed with a single eyedropper. It
- 6 amounts to a teaspoon in a half gallon. And the FDA
- 7 has -- the FDA has explained in this case that it has no
- 8 expertise, it has no warrant to interpret or understand
- 9 or apply judgments about what kind of words and symbols
- 10 and the combination thereof, to use the language of the
- 11 Lanham Act, will have a tendency to misrepresent the
- 12 nature or quality of the goods from the perspective of
- 13 the competitor. And that's --
- 14 JUSTICE KENNEDY: Do you agree that if you
- 15 brought this suit under state law, it would be
- 16 preempted?
- 17 MR. WAXMAN: We think it certainly would not
- 18 be preempted under state law. The state law provision,
- 19 Justice Kennedy, is Section 110660 of the California
- 20 Health and Safety Code, which -- the language of which
- 21 is in haec verba with the very first subsection of the
- 22 misbranding statute 343(A), which declares misbranded
- 23 any label which is false in particular -- false and
- 24 misleading in any particular. That subsection is not
- 25 even the subject -- it's excluded from the limited

- 1 preemption provisions of the NLEA. So it certainly
- 2 wouldn't be preempted. There might be an open question
- 3 if one of the things that we were challenging in the
- 4 course of that state lawsuit was the name itself, and
- 5 the question then would be is this name, in fact,
- 6 compliant with the FDA regulation?
- Now, we've explained in our brief that there
- 8 are three reasons why it is not compliant. And the
- 9 United States agrees that a remand would be appropriate
- 10 in any case to determine whether it is compliant. But
- 11 generally speaking, our state law claim wouldn't be
- 12 preempted at all. Not only is it parallel to the
- 13 misbranding provision, but the provision that it's
- 14 parallel to is not preempted.
- Unless the Court has further questions, I
- 16 would like to reserve the balance of my time.
- 17 CHIEF JUSTICE ROBERTS: Thank you, Counsel.
- 18 Ms. Sherry.
- 19 ORAL ARGUMENT OF MELISSA ARBUS SHERRY,
- 20 FOR UNITED STATES, AS AMICUS CURIAE,
- 21 SUPPORTING NEITHER PARTY
- Mr. Chief Justice, and may it
- 23 please the Court:
- 24 If I could start with the naming aspect of
- 25 the case. Justice Kagan, you are exactly right. We

- 1 have a circumstance here where we have two Federal
- 2 statutes that cover the same subject matter that apply
- 3 functionally the same standard to the same words on the
- 4 same product label.
- 5 Under the FDCA, we have an authoritative
- 6 interpretation of that language by the FDA. 102.33 is a
- 7 regulation that was reached after extensive rule-making
- 8 proceedings over the course of 25 years. The FDA
- 9 considered the exact same question that is being raised
- 10 here. It looked to figure out what an appropriate
- 11 common or usual name was for a juice blend that had a
- 12 small amount of a highly flavorful and expensive juice
- in order to allow consumers to know -- in order to
- 14 prevent consumers from being misled as to the juice
- 15 content of that particular product.
- 16 JUSTICE ALITO: What public health benefit
- 17 is served by this regulation? This is what puzzles me
- 18 about it.
- 19 MS. SHERRY: The regulations comes under the
- 20 misbranding provisions of the FDCA. So 343 focuses on
- 21 misbranding. It has a number of subsections, one of
- 22 which gives the FDA authority to establish common or
- 23 usual names of products. And the purpose of that is to
- 24 have some form of standardization so that when a
- 25 consumer goes to a marketplace to purchase a particular

- 1 product, it knows what is going to be in the product.
- 2 And, in fact, that was the purpose of the very
- 3 regulation at issue here, the idea being by allowing
- 4 manufacturers to choose to name their juice product
- 5 based on the juice that flavors the product as opposed
- 6 to based on the juice that is predominant by volume,
- 7 that consumers will come to understand that when a juice
- 8 says pomegranate and blueberry flavored, what it means
- 9 is that the juice is present as a flavor.
- 10 JUSTICE SOTOMAYOR: Excuse me. I'm not sure
- 11 that -- I mean, the argument is you can't even taste
- 12 these flavors. That's their point. And you are taking
- 13 a contrary point, that the flavor doesn't mean what you
- 14 taste, flavor means something else.
- 15 MS. SHERRY: No, no. The point is -- and I
- 16 think the argument that Petitioner is making has to do
- 17 with the particular facts of this case. The argument is
- 18 because there is only 0.3 percent of pomegranate juice,
- 19 that it is not actually enough to flavor the beverage.
- 20 And that's a factual question that could be resolved on
- 21 remand. But Petitioner's argument with respect to the
- 22 name would be exactly the same, Justice Alito, if there
- 23 was 10 percent of pomegranate juice in this product or
- there was 15 percent. In Petitioner's view, a Lanham
- 25 Act claim could still go forward in those circumstances

- 1 because there would be no irreconcilable conflict.
- 2 JUSTICE SOTOMAYOR: Then, Ms. Sherry, you --
- 3 the government is taking the position that it's okay for
- 4 District Courts to determine whether labels, in fact,
- 5 comply or don't comply with FDA regulations?
- 6 MS. SHERRY: Yes.
- 7 JUSTICE SOTOMAYOR: And if they decide they
- 8 don't comply, that's when they can could permit a Lanham
- 9 Act claim?
- 10 MS. SHERRY: That's correct. And let me try
- 11 to explain why I don't think that's inconsistent with
- 12 the notion of the FDA having exclusive enforcement
- 13 authority with respect to the FDCA. This is still a
- 14 Lanham Act claim. So the only thing that is being
- 15 enforced is the Lanham Act. The FDCA and the FDA
- 16 regulations come up by virtue of the preclusion defense
- 17 that is being raised by Respondents here. And so in the
- 18 course of adjudicating that defense, we agree that
- 19 district courts can look to the FDA regulations to
- 20 determine compliance, of course, by applying all the
- 21 normal rules of deference that would otherwise apply in
- 22 those circumstances. And as my colleague --
- 23 JUSTICE KENNEDY: Do I understand your
- 24 position to be that then if the label is specifically
- 25 authorized, then the Lanham Act is precluded, but if the

- 1 FDCA has just simply failed to forbid it then it's not?
- 2 Is that your distinction you draw.
- 3 MS. SHERRY: I think so. If I could just
- 4 articulate it --
- 5 JUSTICE KENNEDY: Because if it is, I think
- 6 it's very hard to work with.
- 7 MS. SHERRY: And I will try to articulate it
- 8 slightly differently and explain why we don't think it
- 9 is difficult to work with. What we're saying is that if
- 10 the FDA or the FDCA provisions have specifically
- 11 permitted something here, they've specifically permitted
- 12 this type of name in certain circumstances, that that is
- 13 something that should preclude a Lanham Act claim. To
- 14 the extent the FDCA or the FDA has not spoken to the
- 15 particular issue with any degree of specificity, we
- 16 don't see a problem with the Lanham Act claim going
- 17 forward, because in that case you're not really second-
- 18 quessing any judgment --
- 19 JUSTICE GINSBURG: But, Ms. Sherry, applied
- 20 to this case, so we have -- you said the name is okay,
- 21 pomegranate and blueberry flavored, but you say the
- 22 label is something different from the name and the
- 23 Lanham Act can apply to the label. So what parts of the
- 24 label are you saying are not touched -- are not
- 25 preempted by the FDA laws?

- 1 MS. SHERRY: We're drawing a distinction --
- 2 when we say the name, we mean the actual words
- 3 themselves, "pomegranate blueberry flavored blendified
- 4 juices." When we talk about the label more generally,
- 5 we mean how those words are presented on the label and
- 6 other aspects of the label.
- 7 And if I could point the Court to the Nestle
- 8 warning letter, it's discussed in a number of the
- 9 different briefs and it's cited at footnote 7 of our
- 10 brief. I think my colleague was going to bring it up
- 11 earlier. I actually think this letter proves the very
- 12 distinction that we're trying to make. What the FDA
- 13 said in that letter was that the juice labels at issue
- there were misleading, not because of the name, but
- 15 because how the words of the name were displayed on the
- 16 label, because the words "orange tangerine," for
- 17 example, were placed next to the picture of an orange,
- 18 because they were in close proximity to "100 percent" --
- 19 CHIEF JUSTICE ROBERTS: What if the label
- 20 just had the name on it, nothing else? Could they still
- 21 sue on the ground that the label was misleading?
- MS. SHERRY: Not unless they are able to
- 23 point to something else on the label that was misleading
- 24 aside from the actual words in the name. The difficulty
- 25 we have with the naming aspect of the Lanham Act claim

- 1 here is the arguments that Petitioner is making that
- 2 they should have instead named this "apple grape juice,"
- 3 that they should have instead included the percentage
- 4 declarations, are arguments that the FDA
- 5 specifically considered when it adopted this rule and it
- 6 ultimately objected.
- 7 CHIEF JUSTICE ROBERTS: Does the FDA -- does
- 8 the FDA take into account purely commercial confusion
- 9 when it issues -- when it issued its regulations
- 10 governing the label? Or is it limited solely to the,
- 11 what I would expect, you know, the health and well-being
- 12 concerns?
- 13 MS. SHERRY: It absolutely took into account
- 14 -- into account consumer confusion. There were comments
- 15 with respect to this particular regulation, and the
- 16 commenters were consumers saying that they were
- 17 concerned that they were being misled with respect to
- 18 the juice content.
- 19 CHIEF JUSTICE ROBERTS: What does the FDA
- 20 know about that? I mean, I would understand if it was
- 21 the FTC or something like that, but I don't know that
- 22 the FDA has any expertise in terms of consumer confusion
- 23 apart from any health issues.
- 24 MS. SHERRY: I'm not sure that is right.
- 25 The misbranding provisions, 343(a)(1), speak generally

- 1 about labels that are false or misleading in any
- 2 particular. And in adopting the common or usual name
- 3 here, that is something that the FDA was specifically
- 4 focused on.
- 5 The other point I would make is, in
- 6 the court of appeals in the reply brief at page 23, the
- 7 Petitioner acknowledges and argues that the misleading
- 8 standard for the Lanham Act and for the FDCA are not
- 9 materially different from one another.
- 10 Another point I would make with respect
- 11 to the regulation --
- 12 JUSTICE KAGAN: Ms. Sherry, you know, there
- is no irreconcilable conflict if we view what the FDA
- 14 has done as just setting a floor. And you talk a lot
- 15 about how, oh, the FDA specifically considered this and
- 16 it decided not to do this. You put a lot of emphasis on
- 17 process.
- 18 And I quess my question to you is, is that
- 19 the way you are saying we should know whether the FDA
- 20 has only set a floor or instead has also set a ceiling,
- 21 that we're supposed to look to the process and figure
- 22 out whether the FDA specifically rejected a more
- 23 extensive proposal, a more aggressive proposal?
- 24 MS. SHERRY: No. I think you look to
- 25 whether or not allowing the claim to go forward would

- 1 complement what the agency has done or would actually
- 2 conflict with what the agency has done. And here, we
- 3 think there is a real conflict. We're not talking about
- 4 supplementing the agency's enforcement resources. We're
- 5 talking about supplanting their regulatory judgment in
- 6 the area.
- 7 JUSTICE KAGAN: Well, I guess I don't
- 8 understand that. Why wouldn't it complement? You've
- 9 said here is the floor to make it not misleading, but,
- 10 you know, we are not saying that there are some things
- 11 that, you know, wouldn't mislead a lot of consumers
- 12 anyway, and then the Lanham Act can come in and
- 13 supplement that and really put us in a position where
- 14 nothing is misleading at all.
- 15 MS. SHERRY: Oh, for two reasons. Number
- one, because the agency considered why manufacturers
- 17 would want to actually name their product based on the
- 18 flavor, because consumers actually do care about the
- 19 flavor and they care about the taste. If the product
- 20 had the name "apple grape juice," for example, and it in
- 21 fact tasted like pomegranate blueberry juice, a consumer
- 22 might be very surprised when he came home and had a sip
- 23 of that juice and realized it tasted like something very
- 24 different than what he expected.
- 25 JUSTICE ALITO: You don't think there are a

- 1 lot of people who buy pomegranate juice because of --
- 2 they think it has health benefits and they would be very
- 3 surprised to find when they bring home this bottle
- 4 that's got a big picture of a pomegranate on it and it
- 5 says "pomegranate" on it, that it is -- what is it, less
- 6 than one-half of one percent pomegranate juice?
- 7 MS. SHERRY: And I think --
- 8 JUSTICE ALITO: The FDA didn't think that
- 9 would mislead consumers?
- 10 MS. SHERRY: I think -- I think there is a
- 11 reasonable argument that it may. And if I could just go
- 12 to the second part of my argument here. We've been
- 13 talking all about the naming part of the claim at issue
- 14 here. We agree with Petitioners that the remainder of
- 15 the Lanham Act claim shouldn't be allowed to proceed,
- 16 that it is complementary. We agree with Petitioners
- 17 that the Ninth Circuit decision here adopted an overly
- 18 broad understanding of preclusion.
- Now respondent suggests it doesn't defend the
- 20 Ninth Circuit's decision here in footnote 5 of their
- 21 brief, but it's a little bit hard to see what daylight
- 22 there actually is between the Ninth Circuit's
- 23 approach and that of Respondent. Respondent relies on
- the express preemption clause here, but the express
- 25 preemption clause applies only to State or local law.

- 1 By its terms, it doesn't apply to Federal law and it
- 2 doesn't apply to the Lanham Act.
- 3 CHIEF JUSTICE ROBERTS: Thank you, counsel.
- 4 Ms. Sullivan.
- 5 ORAL ARGUMENT OF KATHLEEN M. SULLIVAN
- 6 ON BEHALF OF THE RESPONDENT
- 7 MS. SULLIVAN: Mr. Chief Justice, and may it
- 8 please the Court:
- 9 The FDCA does not deal just with health.
- 10 Section 341 makes clear that it also and with respect to
- 11 the labeling requirements at issue here, quote,
- 12 "promotes honesty and fair dealing in the interest of
- 13 consumers." And here, the most important data we have
- 14 about what Congress did that's barely been mentioned by
- 15 POM or the government, is the enactment in 1990 of the
- 16 NLEA, the Nutrition Labeling and Education Act, and its
- 17 express preemption provision.
- 18 Now, Justice Kennedy, our position is that
- 19 if POM's suit had been brought as a State law lawsuit,
- 20 it would be precisely preempted by the terms of that
- 21 express preemption provision.
- 22 JUSTICE GINSBURG: But the NLEA provision
- 23 doesn't preempt all State law claims, only some State
- 24 law claims.
- MS. SULLIVAN: That's correct, Justice

- 1 Ginsburg. And it preempts precisely these claims if
- 2 they had been brought As state law claims, because let's
- 3 look at the language of the express preemption
- 4 provision. And To be clear, Coca-Cola's position is very
- 5 narrow. Our position is that were these claims that POM
- 6 is making brought as State law claims, they would be
- 7 expressly preempted, and it cannot be that Congress
- 8 meant to preempt these claims if brought as State law
- 9 claims designed to go above the Federal floor, but
- 10 meant to say never mind --
- 11 JUSTICE KAGAN: Well, why can't it be? I
- 12 mean, there are plenty of statutes which say you can't
- 13 bring State law or Federal law claims. Congress knows
- 14 how to do that. And instead, it said you can only
- 15 not bring State law claims.
- 16 MS. SULLIVAN: In fact, Justice Kagan, it's
- 17 very rare that Congress actually says no State or
- 18 Federal claims.
- 19 JUSTICE KAGAN: They just say no claims or
- 20 no -- notwithstanding any law to the contrary.
- 21 MS. SULLIVAN: Fair enough, Your Honor. But
- 22 you have said in numerous cases in which you have found
- 23 a prior or more general law narrowed by a subsequent or
- 24 more specific law, you have said Congress should not be
- 25 put to the burden every time it enacts a statute of

- 1 looking to the four corners of the U.S. Code and
- 2 figuring out what it might displace. And there is no
- 3 reason --
- 4 JUSTICE GINSBURG: Do you have an example,
- 5 Ms. Sullivan, of a case where Congress precluded some
- 6 State claims and said nothing at all about Federal laws
- 7 in which this Court has held that the express preclusion
- 8 of State law claims implicitly precluded Federal claims?
- 9 MS. SULLIVAN: I cannot, Justice Ginsburg,
- 10 though I can cite to you the most relevant and unbroken
- 11 line of court of appeals authority, which are the
- 12 Federal Railroad Safety Act cases. The Federal Railroad
- 13 Safety Act expressly preempted State law negligence
- 14 claims, and the Fifth, Sixth and Seventh Circuits have
- 15 held, without a competing circuit, that therefore,
- 16 Federal FELA negligence claims must be deemed to be
- 17 precluded, because otherwise, the national scheme of
- 18 uniformity in Federal railroad safety would be
- 19 undermined. So, too, here.
- 20 And if I could just go back, Justice
- 21 Ginsburg, to make sure I answer the question. The
- 22 passage of the NLEA and its express preemption provision
- 23 in 1990 was all about national uniformity. In fact,
- 24 what Congress aimed at in passing that statute was
- 25 the --

- 1 JUSTICE KENNEDY: Is it part of Coke's
- 2 narrow position that national uniformity consists in
- 3 labels that cheat the consumers like this one did?
- 4 MS. SULLIVAN: Justice Kennedy, you have
- 5 perhaps succumbed to Mr. Waxman's attempts to argue his
- 6 jury argument here. We're on a motion to dismiss.
- 7 There is no record. We've put in a brief --
- 8 JUSTICE KENNEDY: I think it's important for
- 9 us to know how the statutes work. And if the statute
- 10 works in the way you say it does and that Coca-Cola
- 11 stands behind this label as being fair to consumers,
- 12 then I think you have a very difficult case to make. I
- 13 think it's relevant for us to ask whether people are
- 14 cheated in buying this product. Because Coca-Cola's
- 15 position is to say even if they are, there's nothing we
- 16 can do about it. Do you still have this -- do you still
- 17 have this label?
- 18 MS. SULLIVAN: Yes, Your Honor. It's
- 19 changed in non-material aspects. There is no aspect
- 20 covered by the claims here that has changed.
- 21 But I just want to be very, very clear on
- 22 what POM is arguing here. POM is arguing -- and,
- 23 Justice Sotomayor, they are not arguing your
- 24 hypothetical. POM is arguing here that it may challenge
- 25 Coca-Cola's name and label under the Lanham Act even if

- 1 that name and label complies with the FDCA and all the
- 2 relevant implementing regulations. So, Justice Kagan,
- 3 this is exactly your case, where POM said it can say
- 4 misbranded under the Lanham Act, even where Coca-Cola
- 5 has complied with all of the authorizations set forth in
- 6 the FDA.
- 7 JUSTICE GINSBURG: But maybe the two acts
- 8 are serving different purposes, Ms. Sullivan. The law
- 9 that you are relying on is supposed to be concerned with
- 10 nutritional information and health claims, not a
- 11 competitor is a competitor losing out because of the
- 12 deception. The consumer is able to buy the Coke product
- 13 much cheaper and the POM product costs more; the
- 14 consumer thinks that they are both the same, so they'll
- 15 buy the cheaper one.
- 16 MS. SULLIVAN: First, Justice Ginsburg, let
- 17 me be clear: Safety is not at issue in this case.
- 18 Safety warnings are especially carved out. Justice
- 19 Alito, if there is a worry about allergies; Chief
- 20 Justice Roberts, if there is a worry about health.
- 21 That's not what we're about here. In fact, the NLEA
- 22 especially -- expressly in 6(c)(2) carved out safety
- 23 warnings from the preemption clause. We're not talking
- 24 here about safety.
- we're talking here about labeling so that

- 1 consumers have adequate information, at the same time as
- 2 manufacturers are not put to the burdens and
- 3 inefficiencies of having constantly shifting labeling
- 4 standards imposed by juries, which ultimately will cost
- 5 more to the consumer.
- 6 JUSTICE SOTOMAYOR: Well, let's -- let's
- 7 assume the following. The FDA just wanted to know what
- 8 the name should be. That's all they are regulating.
- 9 That's the only requirement. And it's not even a
- 10 requirement.
- 11 MS. SULLIVAN: It's an authorization.
- 12 JUSTICE SOTOMAYOR: It's an authorization.
- 13 And that's where I'm having a little bit of difficulty,
- 14 because it's not that you have to use this name, you're
- 15 permitted to use this name under their regulations. But
- 16 why are you permitted to use it in a misleading way?
- 17 That's really the -- I think the government's position,
- 18 which is, if you're using the name in combination with
- 19 other factors in a misleading way that's not a subject
- 20 to the regulation, just the name, then it's actionable
- 21 under the Lanham Act.
- 22 MS. SULLIVAN: Justice Sotomayor and Justice
- 23 Kennedy, I need to make very clear that we believe that
- 24 under the FDCA and the FDA regulations, Coke's label is
- 25 as a matter of law not misleading. And once we reach

- 1 that conclusion under FDCA and FDA, Lanham Act can't
- 2 come in from the side and say, oh, yes, it is, because
- 3 that would undermine the express preemption provision
- 4 that was designed to create national uniformity.
- 5 JUSTICE SOTOMAYOR: Could the government --
- 6 I think what the government is saying nothing about our
- 7 permission goes to the size of the name on the label --
- 8 MS. SULLIVAN: Well, Your Honor --
- 9 JUSTICE SOTOMAYOR: -- that you can break up
- 10 the name of the juice into two different sizes so that
- 11 you are deemphasizing it. It also says that the
- 12 vignette is misleading because it shows products that
- 13 have potentially nothing in their regulations say
- 14 anything about vignettes -- and how they display them.
- 15 It's -- nothing in the regulations talk about using
- 16 purple instead of whatever that color is that the juice
- 17 is, that blue, purple, whatever, instead of the color of
- 18 apple juice. If you use the color of apple juice and
- 19 grapes, it would be a light color.
- 20 MS. SULLIVAN: Justice Sotomayor, there are
- 21 five different attacks that POM has made on our label,
- 22 only two of which were addressed in the lower court.
- 23 And we say that we comply with FDA regulations as to all
- 24 five of them. But more important, compliance doesn't
- 25 matter; what matters is are these of the type covered by

- 1 the provisions of the NLEA preemption provision --
- 2 sorry. Are these of a type covered through the NLEA
- 3 preemption provision?
- 4 JUSTICE SOTOMAYOR: You basically are
- 5 talking about field preemption.
- 6 MS. SULLIVAN: Absolutely not, Your Honor.
- 7 Let me make absolutely clear we do not argue for field
- 8 preemption. We argue that where the NLEA express
- 9 preemption provision would make POM's claims expressly
- 10 preempted under State law, it follows as a matter of
- 11 inference from the national uniform scheme that Congress
- 12 set up, that Lanham Act claims are precluded to the
- 13 extent and only to the extent the state claims would
- 14 have been preempted under if they were brought as state
- 15 law claims.
- Now, Justice Sotomayor, all five of POM's
- 17 issues here -- name, vignette, font size, multiple
- 18 lines, and coloring -- name, vignette, font size,
- 19 multiple lines, and coloring -- every one of those is of
- 20 the type required by certain enumerated sections in the
- 21 NLEA express preemption provision. And POM wants
- 22 something that is not identical.
- Justice Ginsburg, POM doesn't just want to
- 24 enjoin our label. POM at JA61 said: You should have
- 25 called it apple grape juice, not pomegranate blueberry

- 1 juice.
- 2 JUSTICE GINSBURG: Well, Mr. Waxman
- 3 clarified that that's not what they are seeking. They
- 4 just want to say your label is misleading. And is
- 5 there -- what statute or regulation of the FDA says that
- 6 compliance with the permissive regulation of the FDA
- 7 necessarily renders the label non-misleading?
- 8 MS. SULLIVAN: Justice Ginsburg, every
- 9 single aspect of their misleadingness claim is covered
- 10 by specific provisions of the FDCA that have preemptive
- 11 force. Under -- I just want you to focus, if on nothing
- 12 else, because my colleagues on the other side haven't
- 13 even mentioned it, on 21 USC 343-1)(a)(2) and (3), the
- 14 express preemption provision. The express preemption
- 15 provision says --
- 16 CHIEF JUSTICE ROBERTS: Where is that set
- 17 forth in the --
- 18 MS. SULLIVAN: It's set forth, Mr. Chief
- 19 Justice, in the red brief addendum at page 5A.
- 20 CHIEF JUSTICE ROBERTS: Okay.
- 21 MS. SULLIVAN: And if you look at the
- 22 express preemption provision, which is notably called
- 23 "National Uniform Nutrition Labeling," Section (2) and
- 24 Section (3) on 5A over to 6A, set forth those portions
- of the FDCA that will and won't have preemptive force.

- 1 We are living in this case entirely within two sections
- 2 that have preemptive force under this statute, and those
- 3 are sections 343(i) and 343(f). "Name" is covered by
- 4 343(i). "Vignette" is covered by 343(i) because, as the
- 5 Federal Register makes clear, name and vignette were
- 6 thought of together.
- 7 "Font size" is covered by 343(f), which goes
- 8 to the presentation of the name and other printed matter
- 9 on the label. "Multiple lines" is covered by 343(f),
- and "coloring" is covered by 343(i)(2).
- 11 JUSTICE KAGAN: Ms. Sullivan, can I ask --
- 12 if this gets you away from the argument you want to
- 13 make, I apologize for that. But suppose we thought that
- 14 the preemption provision here was utterly irrelevant,
- 15 that it applies to state law and not Federal law, and
- 16 that you can't go around broadening the statute just
- 17 because the purposes behind that statute might be
- 18 thought to apply to something else. So suppose I just
- 19 put that aside. Do you still have any kind of argument?
- 20 MS. SULLIVAN: Yes, Your Honor, we still win
- 21 because of your more general approach to preclusion by
- 22 one Federal statute of another, because the FDA
- 23 regulations as to misbranding here are far more
- 24 specific. Let me back up. The statute of the FDCA and
- 25 the regulations promulgated thereunder are more specific

- 1 than the general misrepresentation provisions of the
- 2 Lanham Act.
- 3 JUSTICE KENNEDY: But you say that even --
- 4 I -- I take it I'm characterizing your position right.
- 5 You say that even if there's a violation of the FDA
- 6 regulations, they still couldn't sue under the Lanham
- 7 Act because that's for the FDA.
- 8 MS. SULLIVAN: We do -- we do not take that
- 9 position here, Your Honor, because it's not presented
- 10 here. We said there might --
- 11 JUSTICE KENNEDY: I thought that was -- I
- 12 thought that was at Page 39 in your brief in a footnote.
- 13 MS. SULLIVAN: Justice Kennedy, let me be
- 14 clear. In this case we believe the Lanham Act claim is
- 15 precluded because POM wants to go above the floor set by
- 16 the FDCA and the FDA req. POM has said repeatedly in
- 17 this case, right through the reply brief -- right
- 18 through its reply brief at Page 17, and I quote, and
- 19 this has been their position the whole time, POM's
- 20 challenge does not depend on the FDCA or FDA's
- 21 regulation.
- Justice Sotomayor, POM is not bringing your
- 23 hypothetical suit where they come in to enforce the FDCA
- 24 and the FDA. Had they done so, we think there might be
- 25 a serious question for you to resolve another day about

- 1 whether that's an end run around 337(a)'s restriction of
- 2 enforcement to the United States and prohibition of
- 3 private lawsuits, but that's not this case.
- 4 JUSTICE GINSBURG: I understood them to say
- 5 they were making a Lanham Act challenge. And there is
- 6 no judicial review of the FDA regulations. There's no
- 7 private right of action under the FDA.
- 8 MS. SULLIVAN: Correct, Your Honor.
- 9 JUSTICE GINSBURG: So they are not saying,
- 10 We're bringing an action under the FDCA or the NLEA.
- 11 They say, We're bringing a Lanham Act.
- MS. SULLIVAN: Correct, Your Honor.
- But what I'm trying to say here is, to the
- 14 extent their Lanham Act claims seeks to say, as Justice
- 15 Kagan said before, You are misbranded for
- 16 misrepresentations under the Lanham Act, even though
- 17 Coke has not been misbranded and has not made
- 18 misrepresentations under FDCA and the FDA regulations,
- 19 that is a conflict that should be resolved by this Court
- 20 in the usual manner that statutory construction
- 21 conflicts are resolved by making the statutes make sense
- 22 together.
- 23 CHIEF JUSTICE ROBERTS: I don't know why --
- 24 I don't know why it's impossible to have a label that
- 25 fully complies with the FDA regulations and also happens

- 1 to be misleading on the entirely different question of
- 2 commercial competition, consumer confusion that has
- 3 nothing to do with health.
- 4 MS. SULLIVAN: Mr. Chief Justice, as I said
- 5 before, the FTC in Section 341 as codified expressly
- 6 refers to maintaining honesty for the consumer as well
- 7 as health. But just let me suggest why there is still a
- 8 conflict, and irreconcilable conflict is not the
- 9 touchstone. You have never required irreconcilable
- 10 conflict in -- in all the cases we have cited in our
- 11 brief, Fausto and Elgin, Keogh, Romani, Daystar. You've
- 12 never required irreconcilable conflict. You've
- 13 recognized that one federal statute, if more specific,
- 14 may narrow the scope of a more general statute where
- 15 there is a conflict.
- And there is a conflict here, Your Honor.
- 17 Just to be clear, what Congress wanted was national
- 18 uniformity so that a manufacturer could print one label
- 19 and sell in the 50 states and not have its juice legal
- 20 when you leave on the flight in California and
- 21 illegal when you land in D.C. That national uniformity
- 22 bill --
- 23 JUSTICE KENNEDY: Well, the Lanham -- the
- 24 Lanham Act applies nationally.
- 25 MS. SULLIVAN: Correct, Your Honor, but the

- falsity standard --
- 2 JUSTICE KENNEDY: So you're -- you used a
- 3 state preemption and then say we should apply the same
- 4 principles to two federal statutes --
- 5 MS. SULLIVAN: We do, Your Honor.
- 6 JUSTICE KENNEDY: -- but that's a quite
- 7 different point.
- 8 MS. SULLIVAN: Here's what I'm saying,
- 9 Justice Kennedy. I'm saying after the NLEA express
- 10 preemption provision, a state cannot say that
- 11 pomegranate-blueberry-flavored blend of five juices --
- 12 which is perfectly consistent with the naming
- 13 regulations, as the U.S. agrees. Why is that? Because
- 14 the naming regulations, Justice Sotomayor, said, you can
- 15 name your minority juice, your non-predominant juice in
- 16 either of two ways. You, as a manufacturer, may either
- 17 mention a percentage or --
- 18 JUSTICE KENNEDY: You want us to -- you want
- 19 us to write an opinion that said that Congress enacted a
- 20 statutory scheme because it intended that no matter how
- 21 misleading or how deceptive a label it is, if it passes
- 22 the FDA, it cannot -- it -- there can be no liability.
- 23 That's what you want us to say?
- 24 MS. SULLIVAN: We do not, Your Honor. We
- 25 would want you to say that what misleading is when it is

- 1 defined by FDA in specific regulations pursuant to a
- 2 specific statute that specifically seeks national
- 3 uniformity, in the sense that the manufacturer picks one
- 4 label and doesn't, as the American Beverage Association
- 5 brief says at Page 7, create a logistical nightmare that
- 6 you have to change your label in response to every jury
- 7 verdict. We're saying that once your --
- 8 JUSTICE GINSBURG: Let's suppose there were
- 9 a consumer survey, as there was, but -- and -- and say
- 10 it was a valid survey. And overwhelmingly, consumers
- 11 said that they are misled, that they thought that they
- 12 were getting pure pomegranate, and they were just
- 13 astonished to find what they were getting was apple
- 14 juice with, what Mr. Waxman told us, a dropper of
- 15 blueberry.
- 16 MS. SULLIVAN: Justice --
- 17 JUSTICE GINSBURG: Suppose -- suppose the
- 18 reality is that consumers are misled.
- 19 MS. SULLIVAN: If I suppose that, Your
- 20 Honor, then the proper procedure for a consumer or a
- 21 competitor is to go to the FDA and seek FDA's change of
- 22 its rulemaking. Your Honor, in the red addendum -- red
- 23 brief addendum at Page 17(a) over to 18(a), you'll see
- that in 21 CFR 102.33(d) FDA said, Your juice will not
- 25 be misleading if it uses the word "flavored."

- 1 And in fact, over on 18(a), if you want to
- 2 see the closest thing to an express authorization of our
- 3 label here, it's the example that FDA gave on 18(a). It
- 4 said, You can use either flavor or a percentage, and it
- 5 won't be misleading. Why? Because we don't think that
- 6 consumers are quite as unintelligent as POM must think
- 7 they are. They know when something is a favored blend
- 8 of five juices, non-min- -- the non-predominant juices
- 9 are just a flavor.
- 10 JUSTICE KENNEDY: Don't make me feel bad
- 11 because I thought that this was pomegranate juice.
- 12 (Laughter.)
- 13 MS. SULLIVAN: Justice Kennedy -- Justice
- 14 Kennedy, it's pomegranate-blueberry-flavored blend of
- 15 five juices. I've found that oftentimes -- well --
- 16 JUSTICE SCALIA: He sometimes doesn't read
- 17 closely enough.
- 18 (Laughter.)
- 19 MS. SULLIVAN: Yeah,
- 20 pomegranate-blueberry-flavored blend of five juices.
- 21 And the key point here --
- JUSTICE SOTOMAYOR: How do we square this
- 23 with Wyeth?
- 24 MS. SULLIVAN: Your Honor --
- JUSTICE SOTOMAYOR: Wyeth, the FDA actually

- 1 approves, looks at the label and says, this one is okay.
- 2 Not only is it not misleading, but it complies with all
- 3 health requirements, and because the producers of drugs
- 4 have the ability to change the label without FDA
- 5 approval, there was -- we found no preemptions and no
- 6 impossibility.
- 7 How is Wyeth any different? The FDA here --
- 8 it's even worse, this case. The FDA doesn't approve the
- 9 labels. It never looks at them and says they are okay
- 10 or not okay unless they decide to enforce the statute.
- 11 How is this better than Wyeth?
- 12 MS. SULLIVAN: Two important distinctions,
- 13 Your Honor, but let me first disagree with the premise.
- 14 It's true that FDA doesn't pre-approve the label, but
- 15 they couldn't have gotten closer here, Justice Kennedy,
- 16 than solving your difficulty by saying that
- 17 ras-cranberry juice, it's okay if you call it
- 18 raspberry-and-cranberry-flavored juice drink. You don't
- 19 have to put the percentages in.
- 20 So this is -- it's not a preapproval
- 21 requirement, but these regulations are very specific.
- Justice Sotomayor, Wyeth, as you said, as
- 23 this Court said, did not involve an express preemption
- 24 provision. It is the express preemption provision here
- 25 that says that Congress wanted nationally uniform

- 1 labeling regulations whereby a manufacturer could pick
- 2 one label and stick with it. This is Guyer, not Wyeth.
- 3 JUSTICE SOTOMAYOR: You assume people would
- 4 pick a label and stick with it. The Lanham Act would --
- 5 if a Lanham Act claim is bought, and it's upheld, you
- 6 change the label nationally.
- 7 MS. SULLIVAN: Oh, but, Your Honor, that's
- 8 one thing if the FDA decides to adapt its rulemaking.
- 9 Suppose Justice Ginsberg's consumers or competitors
- 10 showed up and said, Excuse me, we don't think
- 11 ras-cranberry is clear enough. Justice Kennedy said it
- 12 wasn't. Please change your rulemaking.
- 13 When the FDA issues guidance or changes its
- 14 rules or issues a new kind of interpretation, that's one
- 15 agency speaking nationally. What Mr. Waxman wants to do
- 16 is invite plaintiffs to walk into every court in the
- 17 land under Lanham Act claims and create one jury saying,
- 18 I think you should have called it apple-grape juice, and
- 19 another saying you should have had the percentage.
- JUSTICE GINSBURG: Ms. Sullivan, I would like you to
- 21 respond to this question: In the real world, the FDA
- 22 has a tremendous amount of things on its plate, and
- 23 labels for juices are not really high on its list. It
- 24 has very limited resources. You are asking us to take
- 25 what it has said about juice as blessing this label,

- 1 saying it's not misbranding, when its regulations aren't
- 2 reviewed by the Court, when there is no private right of
- 3 action, and say that that overtakes the Lanham Act.
- 4 It's -- it's really very hard to conceive that Congress
- 5 would have done that.
- 6 MS. SULLIVAN: Justice Ginsburg, precisely
- 7 for the reasons you say, you should affirm here and go
- 8 with us in precluding the Lanham Act claims. And the
- 9 reason is that Congress has authorized a very specific
- 10 regulatory regime here. Of course you don't want the
- 11 FDA deciding is pomegranate-blueberry or ras-cranberry
- 12 clear -- that's why they gave specific regulations. And
- 13 contrary to what Mr. Waxman said, the FDA does not just
- 14 have criminal jurisdiction. It has adjudicatory
- 15 jurisdiction. It has civil authority. It can issue
- 16 warning letters, which, as the amicus brief of
- 17 Mr. Friedman points out, are very effective.
- 18 JUSTICE KENNEDY: But the point is that it
- 19 is doubtful that FDA has sufficient resources to police
- 20 food and beverage labeling. I think that was the thrust
- 21 of Justice Ginsburg's question. I had the same concern.
- 22 And this is relevant because we want to see what the
- 23 likely intention of Congress was with reference to these
- 24 two statutes.
- 25 MS. SULLIVAN: Justice Kennedy, the U.S.

- 1 position is unworkable, as you said before. And the
- 2 U.S. hasn't said that they lack sufficient resources.
- 3 What we would respectfully suggest you look at is not
- 4 FDA's latest amicus brief through the U.S., but FDA's
- 5 authoritative statement about whether its labeling
- 6 regulations were being implemented.
- 7 In the red brief at Page 7, we cite to the
- 8 rulemaking in which the FDA found after the three-year
- 9 study -- remember the express preemption provision
- 10 couldn't go into force until there was a three-year
- 11 study by the IOM. And if you look at Page 7 of the red
- 12 brief, three-quarters of the way down the page, you'll
- 13 see FDA in its authoritative statement, irrespective of
- its amicus brief here, found that 343(f), the
- presentation regulation, and 343(i), the naming
- 16 regulation, were being adequately implemented.
- 17 JUSTICE GINSBURG: So that's contrary to its
- 18 current position, and I think we have to take it -- the
- 19 FDA is -- is -- the government is representing the
- 20 current FDA position.
- 21 MS. SULLIVAN: But, Your Honor, you don't
- 22 give our deference to an amicus brief when there's an
- 23 authoritative prior statement by FDA that these
- 24 implementation -- for the very reason you suggest, the
- 25 FDA has other things to do.

- 1 JUSTICE GINSBURG: Would that -- without
- 2 regard to deference, we don't resurrect the statement
- 3 that they no longer support.
- 4 MS. SULLIVAN: Well, Your Honor, they
- 5 haven't disavowed that statement. We would respectfully
- 6 suggest that just as it's too late for Mr. Waxman to
- 7 change his theory, as you said in Riegel, to a -- we're
- 8 enforcing the FDA theory -- and he doesn't purport to do
- 9 it here -- it's -- the FDA, it's too late now to say in
- 10 an amicus brief that they didn't mean it back in 1993.
- 11 JUSTICE KAGAN: Do you think, Ms. Sullivan,
- 12 that there are any Lanham suits regarding food labels
- 13 that are allowable?
- 14 MS. SULLIVAN: Yes, Your Honor. Putting
- 15 aside the private enforcement 337(a) problem that
- 16 Justice Sotomayor raised before, we believe that Lanham
- 17 Act suits are not preempted -- would not be preempted as
- 18 state law claims, and, therefore, are not precluded as
- 19 Lanham Act claims, if they fall outside the specific
- 20 provisions of FDCA that have preemptive force. So
- 21 343(a) -- may I finish, your Honor?
- 22 CHIEF JUSTICE ROBERTS: Yes.
- 23 MS. SULLIVAN: If there is something that is
- 24 not covered -- name, vignette, font, multiplized are
- 25 covered. If there's something else that's not

- 1 covered -- and I would refer Your Honor to --
- 2 specifically to religious dietary labeling, bottle
- 3 container deposit labeling -- those are things that the
- 4 FDA said in its rulemaking, based on the Congressional
- 5 record, are outside the specific provisions with
- 6 preemptive force. Then, assuming there's no 337
- 7 problem, you can have a Lanham Act claim. All we say is
- 8 that --
- 9 CHIEF JUSTICE ROBERTS: Thank you, counsel.
- 10 MS. SULLIVAN: -- the preemption provision
- 11 governs here. Thank you very much.
- 12 CHIEF JUSTICE ROBERTS: Mr. Waxman, you have
- 13 seven minutes remaining.
- 14 REBUTTAL ARGUMENT OF SETH P. WAXMAN
- ON BEHALF OF THE PETITIONER
- 16 MR. WAXMAN: Thank you, Mr. Chief Justice.
- I need to correct a few misstatements by my
- 18 colleague, Ms. Sullivan. First of all, this three-year
- 19 study that she's referring to, as we pointed out in our
- 20 brief, the IOM and the FDA made absolutely clear
- 21 repeatedly in that study that they did not look at FDA's
- 22 enforcement capabilities, its enforcement efforts. It
- 23 had -- it simply was a judgment about whether the
- 24 specific forbearance regulations that they promulgated,
- in fact, adequately accomplished what Congress's

- 1 objectives were.
- 2 Number two, we -- we are not saying that
- 3 this is a misbranded product. We are not trying to
- 4 enforce the FDCA. And the FD -- and the FDA itself has
- 5 made clear, not only in its brief in this case and not
- 6 only in its enforcement action in the Nestle case, but
- 7 in the Federal Register discussion of the juice naming
- 8 regulation, that the fact that the juice may comply --
- 9 and here it probably doesn't -- may comply with the
- 10 naming convention does not mean that it is misleading.
- 11 The FDA said over and over again in that
- 12 rulemaking that we strongly caution manufacturers that,
- in fact, mere compliance with this does not mean that
- 14 the label is misleading and -- and that manufacturers
- 15 are under an obligation to ensure that the label is not
- 16 misleading. Now, as to the question of --
- 17 JUSTICE KENNEDY: Where -- where is that
- 18 statement contained?
- 19 MR. WAXMAN: That is in 58 -- the statements
- 20 that I'm quoting are in 58 Federal Register, Pages 2900,
- 21 2919, and 2920.
- JUSTICE KENNEDY: Thank you.
- MR. WAXMAN: And also, indeed said,
- 24 nonetheless, we encourage manufacturers to name all of
- 25 the juices in a multiple juice product specifically

- 1 because it was concerned about this.
- Now, Ms. Sullivan says, well, you know, not
- 3 all Lanham Act claims are preempt -- precluded. They
- 4 wouldn't be precluded if the parallel cognate state law
- 5 enforcement of an identical standard wouldn't be
- 6 precluded.
- 7 This is -- the closest cognate here is
- 8 343(a), which provides that a food is misbranded if it
- 9 is false -- if the label is false and -- false or
- 10 misleading at any particular. That isn't in this sort
- of Swiss cheese exception -- exemption-filled preemption
- 12 provision of the NLEA. That one isn't preempted. There
- is nothing whatsoever that preempts any person from
- 14 going into state court and enforcing a state law
- provision that recites in haec verba 343(a).
- Now, Ms. Sullivan says, okay, we're not
- 17 worried here. The FDA wasn't worried here about health
- 18 or safety. That's not what's going on here.
- 19 That is the point. That is the point. It's
- 20 because there were concerns about health and safety with
- 21 this juice naming regulation that they said, in the
- 22 exercise of our sovereign enforcement authority, we are
- 23 not going to go after you for complying with this naming
- 24 convention, because, as they've explained, we don't know
- 25 anything about how to protect competitors. We don't

- 1 purport to know what is in the competitive marketplace.
- 2 And we aren't about writing regulations under these
- 3 criminal provisions.
- 4 And Ms. Sullivan is right. There are civil
- 5 enforcement mechanisms, but they're all enforced by
- 6 juries. We aren't going to go this way because this is
- 7 not our job. It's not our expertise. And yet,
- 8 interesting --
- 9 JUSTICE KAGAN: But, Mr. Waxman, I take it that
- 10 Ms. Sherry said that the FDA views itself as having a
- job beyond health and safety, that they view themselves
- 12 as at least -- not thinking about competitors' welfare or
- 13 lack thereof, but at least thinking about consumer
- 14 understanding of labels.
- 15 So if that's the case, is the determination
- 16 under the Lanham Act different from the determination
- 17 under the FDCA?
- 18 MR. WAXMAN: Very definitely, and for -- for
- 19 some of the reasons that this Court discussed in the
- 20 Lexmark case, where you were talking about who can sue
- 21 under the Lanham Act and who's protected. And the Court
- 22 noted that, of course, consumer confusion itself can be
- 23 the engine for a competitive harm.
- 24 But the former is not what the Lanham Act is
- 25 about, and the latter, the FDA has made perfectly clear

- 1 is not what the FDCA is about.
- 2 And interestingly, even with respect to this
- 3 naming provision, and, you know, we -- the government
- 4 agrees with us far more than it disagrees with us, but
- 5 our disagreement about the preclusive effect of their
- 6 judgment is important.
- 7 You know, they say, okay, we -- we spent a
- 8 lot of time on these regulations, and we are entitled to
- 9 chevron deference. And we think they are entitled to
- 10 Chevron deference with respect to interpreting the
- 11 misbranding provisions that they are in fact -- that
- 12 they do enforce.
- 13 They're asking as -- their submission here
- 14 is not -- not -- not just in an FDA action, enforcement
- 15 action in court, will we get chevron deference for our
- interpretation of what the meaning of 343(i)(1) is.
- 17 But in a Lanham Act case, we get chevron on
- 18 steroids deference. We get to basically keep you of out
- 19 of court entire -- you're not even allowed to make that
- 20 claim.
- 21 That is an astonishing proposition, and it
- is one that there is nothing whatsoever in the
- 23 legislative history, the language of the statute,
- 24 anything at all to indicate that Congress wanted --
- 25 JUSTICE KENNEDY: Any authority that the FDA

- 1 interpretation gets deference is presumed to be correct,
- or presumed to be not misleading? Has there ever been
- 3 any scholarship or commentary or cases saying that?
- 4 MR. WAXMAN: Well, certainly not in the
- 5 Lanham Act context. There's been no suggestion that
- 6 they have anything whatsoever to say about the Lanham
- 7 Act. Knowing the professoriate, I'm sure there must be
- 8 some commentary about whether they do or don't get
- 9 chevron deference. But Ms. Sullivan says that they
- 10 don't and the government says that they do. And there
- 11 must be a scholar at least on each side of that
- 12 position, but I simply don't know. I will make one
- 13 final point.
- 14 JUSTICE SCALIA: If there is a Lanham Act
- 15 suit and the regulation is brought forward to prevent
- 16 the suit, cannot the party against whom it's brought
- 17 forward say the regulation is --
- 18 MR. WAXMAN: We certainly intend to say that
- 19 if it becomes relevant, absolutely.
- 20 JUSTICE SCALIA: So it's not on steroids
- 21 then. You can still apply --
- 22 MR. WAXMAN: Well, I -- right. I think that
- 23 it doesn't apply at all. The government would take the
- 24 position that it has preclusive authority.
- Thank you.

1	CHIEF JUSTICE ROBERTS:	Thank yo	ou, Counsel.
2	The case is submitted.		
3	(Whereupon, at 12:07, the case	e in the	
4	above-entitled matter was submitted	•	
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

	I			I
A	46:25	34:13	45:15	benefit 16:16
ability 41:4	adjudicated 5:13	appeals 22:6 27:11	asking 8:9 42:24	benefits 24:2
able 20:22 29:12	adjudicating 18:18	appearances 1:14	50:13	better 4:13 13:9
aboveentitled 1:11	adjudicatory 43:14	apple 12:22 21:2	aspect 15:24 20:25	41:11
52:4	adopted 21:5 24:17	23:20 31:18,18	28:19 33:9	beverage 17:19
absolutely 21:13	adopting 22:2	32:25 39:13	aspects 5:16 20:6	39:4 43:20
32:6,7 46:20	affirm 43:7	applegrape 42:18	28:19	beyond 49:11
51:19	agency 23:1,2,16	applied 19:19	assistant 1:17	big 24:4
accompanied 9:6	42:15	applies 24:25 34:15	association 39:4	bill 37:22
accomplished	agencys 23:4	37:24	assume 30:7 42:3	bit 13:18 24:21
46:25	aggressive 22:23	apply 10:2 11:20	assuming 10:8 46:6	30:13
account 21:8,13,14	agree 14:14 18:18	13:3 14:9 16:2	astonished 39:13	blend 12:12 16:11
acknowledge 6:15	24:14,16	18:21 19:23 25:1	astonishing 50:21	38:11 40:7,14,20
acknowledges 22:7	agrees 3:20 15:9	25:2 34:18 38:3	attacks 31:21	blendified 20:3
act 3:11,17,22 4:1	38:13 50:4	51:21,23	attempt 4:24	blessing 42:25
4:11 5:15 7:13,20	aimed 27:24	applying 6:4 18:20	attempts 28:5	blue 31:17
8:14,16,18 10:8	alito 11:8 12:5 13:7	approach 24:23	authoritative 16:5	blueberry 11:10
10:19 11:13 12:14	16:16 17:22 23:25	34:21	44:5,13,23	12:3,10,19 14:4
13:15 14:11 17:25	24:8 29:19	appropriate 15:9	authority 6:5,8	17:8 19:21 20:3
18:9,14,15,25	alleging 7:20	16:10	9:12 13:3 16:22	23:21 32:25 39:15
19:13,16,23 20:25	allergic 12:7,10,14	approval 41:5	18:13 27:11 43:15	bottle 11:22 12:13
22:8 23:12 24:15	13:12	approve 41:8	48:22 50:25 51:24	24:3 46:2
25:2,16 27:12,13	allergies 29:19	approves 41:1	authorization	bought 42:5
28:25 29:4 30:21	allergy 13:25	april 1:9	30:11,12 40:2	break 31:9
31:1 32:12 35:2,7	allow 8:21 9:12	arbus 1:17 2:6	authorizations	brief 15:7 20:10
35:14 36:5,11,14	10:1 16:13	15:19	29:5	22:6 24:21 28:7
36:16 37:24 42:4	allowable 45:13	area 23:6	authorized 3:18,19	33:19 35:12,17,18
42:5,17 43:3,8	allowed 6:23 24:15	arent 10:19 43:1	18:25 43:9	37:11 39:5,23
45:17,19 46:7	50:19	49:2,6	aware 8:15	43:16 44:4,7,12
48:3 49:16,21,24	allowing 17:3	arguably 12:18	В	44:14,22 45:10
50:17 51:5,7,14	22:25	argue 28:5 32:7,8	back 27:20 34:24	46:20 47:5
action 4:5,19 36:7	american 39:4	argues 22:7	45:10	briefs 20:9
36:10 43:3 47:6	amicus 1:19 2:7	arguing 28:22,22	bad 40:10	bring 4:6 20:10
50:14,15	15:20 43:16 44:4	28:23,24	balance 10:21	24:3 26:13,15
actionable 30:20	44:14,22 45:10	argument 1:12 2:2	15:16	bringing 35:22
actions 10:17,17,18	amount 9:15 14:4	2:5,9,12 3:3,7	barely 25:14	36:10,11
acts 29:7	16:12 42:22	11:18,19 14:1	based 17:5,6 23:17	broad 24:18
actual 20:2,24	amounts 14:6	15:19 17:11,16,17	46:4	broadening 34:16
ad 4:6,9	announce 9:3	17:21 24:11,12	basically 32:4	brought 14:15
adapt 42:8	announcing 5:8 answer 3:17 5:24	25:5 28:6 34:12	50:18	25:19 26:2,6,8
addendum 33:19		34:19 46:14	behalf 1:15,19,22	32:14 51:15,16
39:22,23	6:1,11 27:21	arguments 21:1,4	2:4,7,11,14 3:8	buckman 4:18,20
addressed 31:22	anticipated 3:16	articulate 19:4,7	25:6 46:15	burden 11:15 26:25
adduce 11:14	anyway 23:12	ascertain 5:2 ascribed 9:9	believe 12:2 30:23	burdens 30:2 businesses 3:12
adequate 30:1	apart 21:23		35:14 45:16	
adequately 44:16	apologize 6:19	aside 20:24 34:19	30.11 13.10	buy 24:1 29:12,15
	<u> </u>	l	l	l
	ı	·	·	1

buying 13:18 28:14	42:12 45:7	clarified 33:3	16:11,22 22:2	confusion 21:8,14
buying 13.10 20.14	changed 28:19,20	class 6:10 8:23	company 1:6 3:5	21:22 37:2 49:22
	changes 6:24 42:13	clause 24:24,25	9:25	congress 3:25 8:13
c 1:8,15,18 2:1 3:1	character 3:13 8:19	29:23	, ·	8:15,20,25 9:20
29:22 37:21			competing 27:15	7 7
california 14:19	characterizing 35:4	clear 9:7 25:10	competition 37:2	10:1 25:14 26:7
37:20	cheaper 29:13,15	26:4 28:21 29:17	competitive 49:1	26:13,17,24 27:5
call 41:17	cheat 28:3	30:23 32:7 34:5	49:23	27:24 32:11 37:17
called 32:25 33:22	cheated 28:14	35:14 37:17 42:11	competitor 10:23	38:19 41:25 43:4
42:18	cheese 48:11	43:12 46:20 47:5	14:13 29:11,11	43:9,23 50:24
	chevron 50:9,10,15	49:25	39:21	congressional 3:24
canons 7:1	50:17 51:9	close 20:18	competitors 3:13	46:4
cant 13:10 17:11	chief 3:3,9 15:17,22	closely 40:17	11:16 42:9 48:25	congresss 46:25
26:11,12 31:1	20:19 21:7,19	closer 41:15	49:12	considered 7:6 16:9
34:16	25:3,7 29:19	closest 40:2 48:7	complaint 10:11	21:5 22:15 23:16
capabilities 46:22	33:16,18,20 36:23	cocacola 1:6 3:4	complement 23:1,8	consistent 3:21 5:7
capacity 9:16	37:4 45:22 46:9	11:24 28:10 29:4	complementary	38:12
care 23:18,19	46:12,16 52:1	cocacolas 3:15 26:4	24:16	consists 28:2
carved 29:18,22	choose 17:4	28:14,25	completely 10:4	constantly 30:3
case 3:4,14 4:23 5:4	circuit 24:17 27:15	code 14:20 27:1	compliance 9:14	constituent 13:24
5:20,23 9:21	circuits 24:20,22	codified 37:5	18:20 31:24 33:6	constituted 7:10
10:25 11:13 12:6	27:14	cognate 48:4,7	47:13	construction 7:1
13:8,24 14:7	circumstance 16:1	coke 3:16,16 4:2	compliant 15:6,8	36:20
15:10,25 17:17	circumstances 4:25	5:6 9:22 10:8	15:10	construes 7:22
19:17,20 27:5	5:9 9:19 17:25	29:12 36:17	complied 5:3 29:5	consumer 16:25
28:12 29:3,17	18:22 19:12	cokes 11:18 28:1	complies 29:1	21:14,22 23:21
34:1 35:14,17	cite 27:10 44:7	30:24	36:25 41:2	29:12,14 30:5
36:3 41:8 47:5,6	cited 7:24 9:5 20:9	colleague 18:22	comply 4:3 18:5,5,8	37:2,6 39:9,20
49:15,20 50:17	37:10	20:10 46:18	31:23 47:8,9	49:13,22
52:2,3	civil 10:17 43:15	colleagues 33:12	complying 48:23	consumers 3:15
cases 4:1 11:1	49:4	color 31:16,17,18	components 10:7	9:24 10:23 11:16
26:22 27:12 37:10	claim 7:13 8:10	31:19	comport 4:9	12:2,17 13:5 14:1
51:3	10:8 12:15 13:15	coloring 32:18,19	concede 5:14	14:2 16:13,14
cause 4:5,18	15:11 17:25 18:9	34:10	conceive 43:4	17:7 21:16 23:11
caution 47:12	18:14 19:13,16	combination 14:10	concern 43:21	23:18 24:9 25:13
ceasing 10:12	20:25 22:25 24:13	30:18	concerned 21:17	28:3,11 30:1
ceiling 6:4 22:20	24:15 33:9 35:14	come 9:22 11:14	29:9 48:1	39:10,18 40:6
certain 19:12 32:20	42:5 46:7 50:20	17:7 18:16 23:12	concerns 21:12	42:9
certainly 14:17			48:20	
15:1 51:4,18	claiming 8:10	31:2 35:23		contained 47:18
cfr 39:24	claims 8:8 25:23,24	comes 16:19	conclude 8:20	container 46:3
challenge 5:15	26:1,2,5,6,8,9,13	coming 7:13	conclusion 31:1	content 16:15
28:24 35:20 36:5	26:15,18,19 27:6	commentary 51:3,8	conditioned 3:25	21:18
	27:8,8,14,16	commenters 21:16	conflict 6:25 7:4,19	context 8:14 51:5
challenging 8:5	28:20 29:10 32:9	comments 21:14	18:1 22:13 23:2,3	contrary 17:13
	32:12,13,15 36:14	commercial 21:8	36:19 37:8,8,10	26:20 43:13 44:17
change 6:18 39:6	42:17 43:8 45:18	37:2	37:12,15,16	convention 47:10
39:21 41:4 42:6	45:19 48:3	common 11:5	conflicts 36:21	48:24

	Ī	I	I	i
corners 27:1	d 1:8,15,18 3:1	different 5:4 6:10	drawing 20:1	34:1 37:1
correct 10:16 18:10	37:21 39:24	6:10,13 7:3 8:8,22	drink 13:10,10	entitled 50:8,9
25:25 36:8,12	data 25:13	8:23,23 10:3,3,4	41:18	enumerated 32:20
37:25 46:17 51:1	day 9:7 35:25	11:3 19:22 20:9	dropper 39:14	especially 29:18,22
cost 30:4	daylight 24:21	22:9 23:24 29:8	drugs 41:3	esq 1:15,17,21 2:3
costs 29:13	daystar 37:11	31:10,21 37:1		2:6,10,13
couldnt 35:6 41:15	deal 25:9	38:7 41:7 49:16	E	essentially 6:8 7:10
44:10	dealing 25:12	differently 19:8	e 2:1 3:1,1	9:3
counsel 15:17 25:3	deception 29:12	difficult 19:9 28:12	earlier 20:11	establish 11:18
46:9 52:1	deceptive 38:21	difficulty 20:24	earth 14:3	16:22
count 8:4	decide 6:25 18:7	30:13 41:16	easy 4:2	evidence 10:22
counterfactually	41:10	direct 7:19	economic 9:24	11:15 12:1
6:20	decided 7:8 11:5	disadvantage 9:24	education 25:16	exact 16:9
counts 7:11,12	22:16	disagree 41:13	effect 3:23 50:5	exactly 7:8 15:25
course 5:1 10:11,13	decides 42:8	disagreement 50:5	effective 43:17	17:22 29:3
12:16 15:4 16:8	deciding 4:8 43:11	disagrees 50:4	efforts 46:22	examined 5:23 6:21
18:18,20 43:10	decision 6:2 8:22	disavowed 45:5	egregious 3:14	examining 7:23
49:22	10:2 24:17,20	disclose 12:20	either 38:16,16	example 20:17
court 1:1,12 3:10	declarations 21:4	discussed 20:8	40:4	23:20 27:4 40:3
4:7,17,20 5:1,12	declares 14:22	49:19	elgin 37:11	exception 48:11
6:25 7:25 9:22,22	deemed 27:16	discussion 47:7	emphasis 22:16	excluded 14:25
15:15,23 20:7	deemphasizing	dismiss 28:6	enacted 8:16 38:19	exclusive 18:12
22:6 25:8 27:7,11	31:11	dispensed 14:5	enactment 8:15	excuse 17:10 42:10
31:22 36:19 41:23	defend 24:19	displace 27:2	25:15	exemptionfilled
42:16 43:2 48:14	defense 18:16,18	display 31:14	enactments 3:24	48:11
49:19,21 50:15,19	deference 18:21	displayed 20:15	enacts 26:25	exercise 48:22
courts 3:23 5:13	44:22 45:2 50:9	distinction 19:2	encourage 9:17,18	exercising 5:10
6:2 18:4,19	50:10,15,18 51:1	20:1,12	47:24	exists 10:13
cover 16:2	51:9	distinctions 41:12	enforce 4:5,19,24	expect 21:11
covered 8:6 28:20	defined 39:1	distinguished 4:20	35:23 41:10 47:4	expected 23:24
31:25 32:2 33:9	definitely 49:18	district 18:4,19	50:12	expensive 16:12
34:3,4,7,9,10	degree 19:15	doesnt 4:9 13:1	enforced 18:15	expertise 14:8
45:24,25 46:1	department 1:18	17:13 24:19 25:1	49:5	21:22 49:7
create 6:8 31:4 39:5	depend 35:20	25:2,23 31:24	enforcement 3:25	explain 3:19 18:11
42:17	deposit 46:3	32:23 39:4 40:16	6:9 7:24 9:3,12	19:8
created 9:25	design 11:24	41:8,14 45:8 47:9	18:12 23:4 36:2	explained 4:18 5:12
criminal 5:8,10	designed 9:23 26:9	51:23	45:15 46:22,22	14:7 15:7 48:24
10:17 13:2 43:14	31:4	dont 9:4 11:18 18:5	47:6 48:5,22 49:5	explains 5:1
49:3	determination	18:8,11 19:8,16	50:14	express 8:14 24:24
curiae 1:19 2:8	49:15,16	21:21 23:7,25	enforcing 45:8 48:14	24:24 25:17,21
15:20	determine 15:10	36:23,24 40:5,10		26:3 27:7,22 31:3
current 44:18,20	18:4,20	41:18 42:10 43:10	engine 49:23	32:8,21 33:14,14
currently 10:13	detriment 11:17	44:21 45:2 48:24	enjoin 32:24 ensure 47:15	33:22 38:9 40:2
customers 13:16	didnt 6:19 8:25	48:25 51:8,10,12	ensure 47:15 entire 50:19	41:23,24 44:9
D	10:11 24:8 45:10	doubtful 43:19		expressly 26:7
	dietary 46:2	draw 19:2	entirely 4:2,2 5:5	27:13 29:22 32:9
		<u> </u>		l

37:5	31:1,23 33:5,6	17:19 23:18,19	g 3:1	green 14:3
extensive 16:7	34:22 35:5,7,16	40:4,9	gallon 14:6	grossly 3:15 9:24
22:23	35:24 36:6,7,18	flavored 17:8 19:21	general 1:18 7:5	ground 13:15 20:21
extent 19:14 32:13	36:25 38:22 39:1	20:3 39:25	26:23 34:21 35:1	guess 22:18 23:7
32:13 36:14	39:21,24 40:3,25	flavorful 16:12	37:14	guessing 19:18
eye 13:3	41:4,7,8,14 42:8			guidance 42:13
	′ ′ ′	flavors 17:5,12	generally 15:11 20:4 21:25	S
eyedropper 12:11 14:5	42:13,21 43:11,13	flight 37:20		guyer 42:2
1 -	43:19 44:8,13,19	floor 6:4 22:14,20	getting 39:12,13 ginsbergs 42:9	H
eyedroppers 11:21	44:20,23,25 45:8	23:9 26:9 35:15		haec 14:21 48:15
F	45:9 46:4,20 47:4	focus 7:4 33:11	ginsburg 10:6,14 19:19 25:22 26:1	half 14:6
f 34:3,7,9 44:14	47:11 48:17 49:10	focused 22:4		halfgallon 11:22
fact 3:19 4:2 5:13	49:25 50:14,25	focuses 16:20	27:4,9,21 29:7,16	happens 36:25
6:18 7:22 8:16	fdas 6:3 7:23 35:20	following 30:7	32:23 33:2,8 36:4	hard 11:11,12 19:6
9:10,23 12:3	39:21 44:4,4	follows 32:10	36:9 39:8,17	24:21 43:4
13:23 14:2 15:5	46:21	font 32:17,18 34:7	42:20 43:6 44:17	harm 10:22 49:23
17:2 18:4 23:21	fdca 4:19 5:13 6:3	45:24	45:1	hasnt 44:2
26:16 27:23 29:21	9:1 10:17 12:24	food 4:1 5:16 8:19	ginsburgs 43:21	havent 33:12 45:5
40:1 46:25 47:8	16:5,20 18:13,15	11:1 43:20 45:12	give 3:23 7:2 10:19	health 12:24 14:20
47:13 50:11	19:1,10,14 22:8 25:9 29:1 30:24	48:8 footnote 20:0 24:20	44:22	16:16 21:11,23
factors 30:19		footnote 20:9 24:20	given 13:1	24:2 25:9 29:10
facts 9:21 17:17	31:1 33:10,25	35:12	gives 16:22	29:20 37:3,7 41:3
factual 17:20	34:24 35:16,20,23	forbearance 9:4,11	go 4:8 17:25 22:25	48:17,20 49:11
failed 19:1	36:10,18 45:20	13:3 46:24	24:11 26:9 27:20	healthier 13:11
fair 25:12 26:21	47:4 49:17 50:1	forbid 19:1	34:16 35:15 39:21	hear 3:3
28:11	federal 6:9 9:5,13	force 33:11,25 34:2	43:7 44:10 48:23	held 4:21 27:7,15
fall 45:19	16:1 25:1 26:9,13	44:10 45:20 46:6	49:6	heres 38:8
false 14:23,23 22:1	26:18 27:6,8,12	forebear 5:9 form 16:24	gods 14:3	high 42:23
48:9,9,9	27:12,16,18 34:5	former 49:24	goes 16:25 31:7 34:7	higher 11:9
falsity 38:1	34:15,22 37:13			highly 16:12
far 34:23 50:4	38:4 47:7,20	forth 29:5 33:17,18 33:24	going 5:1 13:4,5,16 17:1 19:16 20:10	history 7:24 50:23
fausto 37:11	feel 40:10			home 23:22 24:3
favored 40:7	fela 27:16	forward 17:25	48:14,18,23 49:6	honesty 25:12 37:6
fd 11:7 47:4	field 32:5,7 fifth 27:14	19:17 22:25 51:15	goods 3:13 14:12	honor 5:11 26:21
fda 3:18,21 4:5,6		51:17	gotten 41:15	28:18 31:8 32:6
5:9,16,23 6:5,5,20	figure 4:14 16:10	found 26:22 40:15	governing 21:10	34:20 35:9 36:8
7:5,11,14,17,19	22:21 Farming 27:2	41:5 44:8,14	government 5:1	36:12 37:16,25
7:22 8:2,11,21,25	figuring 27:2	four 27:1	9:11 18:3 25:15	38:5,24 39:20,22
9:2 10:1 12:11,23	final 51:13	friedman 43:17	31:5,6 44:19 50:3	40:24 41:13 42:7
13:1,13,22 14:6,7	find 24:3 39:13	front 12:17	51:10,23	44:21 45:4,14,21
15:6 16:6,8,22	fine 6:6 8:3 finish 45:21	ftc 21:21 37:5 full 3:23 12:11	governments 11:19 30:17	46:1
18:5,12,15,19	first 14:21 29:16	fully 36:25		hypothetical 13:21
19:10,14,25 20:12	41:13 46:18	functionally 16:3	governs 46:11	28:24 35:23
21:4,7,8,19,22		further 15:15	grape 12:22 21:2	hypothetically 8:1
22:3,13,15,19,22	five 31:21,24 32:16	Turther 13.13	23:20 32:25	
24:8 29:6 30:7,24	38:11 40:8,15,20	G	grapes 31:19	I
2 27.0 30.7,24	flavor 17:9,13,14		great 9:16	_
	ı	<u> </u>	ı	ı

15.3
idea 17:3
identical 32:22
48:5
illegal 37:21
im 4:14 8:9 11:7
12:8 13:7 17:10
21:24 30:13 35:4
36:13 38:8,9
47:20 51:7
immunity 6:8
implementation
44:24
implemented 44:6
44:16
implementing 29:2
implements 5:8
implicitly 27:8
important 8:24
25:13 28:8 31:24
41:12 50:6
imposed 4:22 30:4
impossibility 6:16
7:2 41:6
impossible 36:24
inadvertently
12:13
included 21:3
inconsistent 18:11
indicate 50:24
indication 8:13
indicator 8:25
industry 8:17
inefficiencies 30:3
inference 32:11
information 29:10
30:1
ingredients 12:7
injunction 10:12
injunctive 10:7
inquiry 10:3
instance 4:23 5:11
6:24
intend 51:18
intended 8:20 9:20
38:20
intention 43:23

intentionally 9:23 interest 25:12 interesting 49:8 interestingly 50:2 **interpret** 13:3 14:8 interpretation 16:6 42:14 50:16 51:1 interpreting 4:8 6:3 50:10 **invite** 42:16 involve 11:1 41:23 involved 7:7 **involving** 4:23 5:4 iom 44:11 46:20 irreconcilable 6:25 18:1 22:13 37:8,9 37:12 irrelevant 5:6 34.14 irrespective 44:13 isnt 7:3,15,16 13:6 48:10,12 issue 6:16 17:3 19:15 20:13 24:13 25:11 29:17 43:15 **issued** 21:9 issues 21:9,23 32:17 42:13,14 ive 40:15

J ja61 32:24 **job** 49:7,11 judgment 9:4 10:21 12:23 19:18 23:5 46:23 50:6 judgments 10:20 14:9 judicial 36:6 juice 9:6,16 11:21 12:3,10,10,19,19 12:22,22 13:9,14 13:17 14:4 16:11 16:12,14 17:4,5,6 17:7,9,18,23 20:13 21:2,18

23:20,21,23 24:1 24:6 31:10.16.18 31:18 32:25 33:1 37:19 38:15,15 39:14,24 40:11 41:17,18 42:18,25 47:7,8,25 48:21 juices 9:18 12:4 13:24 20:4 38:11 40:8,8,15,20 42:23 47:25 juries 10:19 30:4 49:6 jurisdiction 43:14 43:15 jury 11:5 28:6 39:6 42:17 justice 1:18 3:3,9 4:4,12,13 5:14,18 5:19,24 6:12,12 7:3,17 8:1,7 10:6 10:14 11:8 12:5 13:7 14:14.19 15:17,22,25 16:16 17:10,22 18:2,7 18:23 19:5,19 20:19 21:7,19 22:12 23:7,25 24:8 25:3,7,18,22 25:25 26:11,16,19 27:4,9,20 28:1,4,8 28:23 29:2,7,16 29:18,20 30:6,12 30:22,22 31:5,9 31:20 32:4,16,23 33:2,8,16,19,20 34:11 35:3,11,13 35:22 36:4,9,14 36:23 37:4,23 38:2,6,9,14,18 39:8,16,17 40:10 40:13,13,16,22,25 41:15,22 42:3,9 42:11,20 43:6,18 43:21,25 44:17

46:9,12,16 47:17 47:22 49:9 50:25 51:14,20 52:1 K **kagan** 6:12 7:3,17 8:1,7 15:25 22:12 23:7 26:11,16,19 29:2 34:11 36:15 45:11 49:9 kathleen 1:21 2:10 25:5 keep 50:18 kennedy 5:14,18,19 5:24 14:14,19 18:23 19:5 25:18 28:1,4,8 30:23 35:3,11,13 37:23 38:2,6,9,18 40:10 40:13,14 41:15 42:11 43:18,25 47:17,22 50:25 kennedys 6:12 keogh 37:11 key 40:21 kind 7:4,8,9 12:23 14:9 34:19 42:14 kinds 13:4 knew 9:22 know 4:16 5:19 7:21,22 12:8,17 16:13 21:11,20,21 22:12,19 23:10,11 28:9 30:7 36:23 36:24 40:7 48:2 48:24 49:1 50:3,7 51:12 knowing 51:7 knows 11:24 17:1 26:13 L label 3:15,17,18 4:5

5:6,16 6:6,6,14,14

6:19,21 8:5,9 9:23

10:13,14 11:4,6

12:2,18,21 14:23 16:4 18:24 19:22 19:23,24 20:4,5,6 20:16,19,21,23 21:10 28:11,17,25 29:1 30:24 31:7 31:21 32:24 33:4 33:7 34:9 36:24 37:18 38:21 39:4 39:6 40:3 41:1,4 41:14 42:2,4,6,25 47:14,15 48:9 **labeling** 4:1 8:16 25:11,16 29:25 30:3 33:23 42:1 43:20 44:5 46:2,3 labels 18:4 20:13 22:1 28:3 41:9 42:23 45:12 49:14 lack 44:2 49:13 land 37:21 42:17 language 10:3 14:10,20 16:6 26:3 50:23 lanham 3:11,17,22 4:1,10 5:15 7:13 7:20 8:14,18 10:8 10:18 11:13 12:14 13:15 14:11 17:24 18:8,14,15,25 19:13,16,23 20:25 22:8 23:12 24:15 25:2 28:25 29:4 30:21 31:1 32:12 35:2,6,14 36:5,11 36:14,16 37:23,24 42:4,5,17 43:3,8 45:12,16,19 46:7 48:3 49:16,21,24 50:17 51:5,6,14 **large** 9:25 largely 3:20 late 45:6,9 latest 44:4 laughter 40:12,18

law 3:15 4:22,24,25

45:1,11,16,22

	•	•	•	
11:5 14:15,18,18	lower 31:22	minutes 46:13	name 7:4 8:2,3 9:9	38:9 48:12
15:11 24:25 25:1		misappropriated	9:9,16,18 11:20	nonmaterial 28:19
25:19,23,24 26:2	M	3:12	13:23 15:4,5	nonmin 40:8
26:6,8,13,13,15	m 1:13,21 2:10 3:2	misbranded 14:22	16:11 17:4,22	nonmisleading
26:20,23,24 27:8	25:5	29:4 36:15,17	19:12,20,22 20:2	10:9 33:7
27:13 29:8 30:25	maintaining 37:6	47:3 48:8	20:14,15,20,24	nonpredominant
32:10,15 34:15,15	majority 12:4	misbranding 5:12	22:2 23:17,20	9:16 38:15 40:8
45:18 48:4,14	13:16	7:10,11,12,14,18	28:25 29:1 30:8	normal 18:21
lawful 10:15	making 17:16 21:1	7:18 8:3,4 9:1	30:14,15,18,20	notably 33:22
laws 10:18 19:25	26:6 36:5,21	14:22 15:13 16:20	31:7,10 32:17,18	noted 49:22
27:6	manner 36:20	16:21 21:25 34:23	34:3,5,8 38:15	notion 9:19 10:1
lawsuit 15:4 25:19	manufacturer	43:1 50:11	45:24 47:24	18:12
lawsuits 36:3	11:23 37:18 38:16	mislead 9:16 13:5	named 21:2	notwithstanding
leave 37:20	39:3 42:1	23:11 24:9	names 7:8 16:23	26:20
legal 37:19	manufacturers	misleading 11:25	naming 9:6 15:24	number 10:23
legislative 50:23	9:14,18 17:4	14:2,24 20:14,21	20:25 24:13 38:12	11:16 12:6 16:21
letter 20:8,11,13	23:16 30:2 47:12	20:23 22:1,7 23:9	38:14 44:15 47:7	20:8 23:15 47:2
letters 43:16	47:14,24	23:14 30:16,19,25	47:10 48:21,23	numerous 26:22
levine 11:2	market 3:12 9:25	31:12 33:4 37:1	50:3	nutrition 8:16
lexmark 49:20	marketplace 13:6	38:21,25 39:25	narrow 26:5 28:2	25:16 33:23
liability 38:22	16:25 49:1	40:5 41:2 47:10	37:14	nutritional 29:10
light 31:19	materially 22:9	47:14,16 48:10	narrowed 26:23	
limited 5:9 7:23	matter 1:11 11:19	51:2	national 27:17,23	0
14:25 21:10 42:24	16:2 30:25 31:25	misleadingness	28:2 31:4 32:11	o 2:1 3:1
line 27:11	32:10 34:8 38:20	33:9	33:23 37:17,21	objected 21:6
lines 32:18,19 34:9	52:4	misleads 3:15 9:24	39:2	objection 13:25
list 42:23	matters 31:25	misled 10:24 11:17	nationally 37:24	objectives 47:1
little 13:18 24:21	mean 8:25 10:5,11	11:17 13:17 14:1	41:25 42:6,15	obligated 3:23
30:13	11:13,22 13:25	16:14 21:17 39:11	nature 13:2 14:12	obligation 47:15
living 34:1	17:11,13 20:2,5	39:18	necessarily 33:7	obligations 4:3
llc 1:3	21:20 26:12 45:10	misrepresent 3:13	need 3:16 30:23	oftentimes 40:15
local 24:25	47:10,13	14:11	46:17	oh 22:15 23:15 31:2
logistical 39:5	meaning 50:16	misrepresentation	negligence 27:13	42:7
lohr 4:20	means 17:8,14	35:1	27:16	okay 9:10 18:3
long 7:7	meant 26:8,10	misrepresentations	neither 1:20 2:8	19:20 33:20 41:1
longer 45:3	mechanisms 49:5	8:19 36:16,18	15:21	41:9,10,17 48:16
look 12:2 18:19	medtronic 4:20	misstatements	nestle 20:7 47:6	50:7
22:21,24 26:3	melissa 1:17 2:6	46:17	never 3:25 5:23	omb 8:17
33:21 44:3,11	15:19	monday 1:9	26:10 37:9,12	once 30:25 39:7
46:21	mention 38:17	motion 28:6	41:9	onehalf 24:6
looked 16:10	mentioned 25:14	multiple 32:17,19	new 1:21,21 42:14	open 15:2
looking 27:1	33:13	34:9 47:25	nightmare 39:5	opinion 38:19
looks 41:1,9	mere 47:13	multiplized 45:24	ninth 24:17,20,22	opposed 17:5
losing 29:11	microns 11:22		nlea 15:1 25:16,22	oppositefacing 7:1
lot 11:9 22:14,16	mind 26:10	<u>N</u>	27:22 29:21 32:1	oral 1:11 2:2,5,9
23:11 24:1 50:8	minority 38:15	n 2:1,1 3:1	32:2,8,21 36:10	3:7 15:19 25:5

orange 20:16,17	49:25	24:1,4,5,6 32:25	25:17,21 26:3	9:19 10:9 11:17
order 16:13,13	permission 31:7	39:12 40:11	27:22 29:23 31:3	14:5 16:4,15 17:1
outside 45:19 46:5				,
	permissions 9:2	pomegranateblu 43:11	32:1,3,5,8,9,21	17:1,4,5,23 23:17
overly 24:17	permissive 33:6		33:14,14,22 34:14	23:19 28:14 29:12
overtakes 43:3	permit 18:8	pomegranateblu	38:3,10 41:23,24	29:13 47:3,25
overwhelmingly	permitted 6:21 7:6	38:11 40:14,20	44:9 46:10 48:11	products 8:19
39:10	7:8,9 10:19 19:11	poms 25:19 32:9,16	preemptions 41:5	16:23 31:12
P	19:11 30:15,16	35:19	preemptive 33:10	professoriate 51:7
	person 48:13	population 13:9,12	33:25 34:2 45:20	prohibition 36:2
p 1:15 2:3,13 3:1,7	perspective 12:1	portions 33:24	46:6	prohibitions 5:8
46:14	14:12	position 18:3,24	preempts 26:1	9:1
page 2:2 22:6 33:19	petitioner 1:4,16	23:13 25:18 26:4	48:13	prominently 12:12
35:12,18 39:5,23	2:4,14 3:8 17:16	26:5 28:2,15	premise 41:13	promotes 25:12
44:7,11,12	21:1 22:7 46:15	30:17 35:4,9,19	prescriptive 10:20	promulgate 13:22
pages 47:20	petitioners 17:21	44:1,18,20 51:12	present 17:9	promulgated 9:3
parallel 4:22,24 5:2	17:24 24:14,16	51:24	presentation 34:8	34:25 46:24
10:18 15:12,14	pharmaceuticals	possibility 6:18	44:15	promulgation 9:6
48:4	6:23	possible 3:24 4:2	presented 20:5	pronouncement
part 9:25 24:12,13	pick 42:1,4	possibly 11:13	35:9	9:8
28:1	picks 39:3	potential 13:16	presents 3:14	proper 39:20
particular 4:9 5:7	picture 20:17 24:4	potentially 31:13	presumably 13:21	proposal 22:23,23
10:25 11:6 14:23	placed 20:17	preapproval 41:20	13:22	proposition 50:21
14:24 16:15,25	plaintiff 5:15 11:2	preapprove 41:14	presumed 51:1,2	protect 12:24 48:25
17:17 19:15 21:15	plaintiffs 42:16	precisely 25:20	prevail 11:13	protected 49:21
22:2 48:10	plate 42:22	26:1 43:6	prevent 16:14	protects 6:9 8:23
particularly 13:1	please 3:10 15:23	preclude 9:21	51:15	prove 3:22
parties 7:24	25:8 42:12	19:13	primacy 7:2	proves 20:11
parts 8:8 19:23	plenty 26:12	precluded 3:25	principles 38:4	provided 4:21
party 1:20 2:8	point 17:12,13,15	18:25 27:5,8,17	print 37:18	provides 3:11 48:8
15:21 51:16	20:7,23 22:5,10	32:12 35:15 45:18	printed 34:8	provision 14:18
passage 27:22	38:7 40:21 43:18	48:3,4,6	prior 26:23 44:23	15:13,13 25:17,21
passes 38:21	48:19,19 51:13	precluding 43:8	private 4:4,18 36:3	25:22 26:4 27:22
passing 27:24	pointed 46:19	preclusion 18:16	36:7 43:2 45:15	31:3 32:1,3,9,21
penalties 5:10	points 43:17	24:18 27:7 34:21	probably 47:9	33:14,15,22 34:14
people 8:24 12:7,9	police 8:18 43:19	preclusive 50:5	problem 7:15,16	38:10 41:24,24
12:13 24:1 28:13	pom 1:3 3:4,21	51:24	10:25 19:16 45:15	44:9 46:10 48:12
42:3	25:15 26:5 28:22	predominant 17:6	46:7	48:15 50:3
percent 11:9 12:21	28:22,24 29:3,13	preempt 25:23 26:8	procedure 39:20	provisions 4:19
12:22 13:8 17:18	31:21 32:21,23,24	48:3	proceed 24:15	5:12 9:1,5 15:1
17:23,24 20:18	35:15,16,22 40:6	preempted 14:16	proceeding 4:6	16:20 19:10 21:25
24:6	pome 12:16	14:18 15:2,12,14	proceedings 16:8	32:1 33:10 35:1
percentage 11:8	pome 12.10 pomegranate 11:9	19:25 25:20 26:7	process 7:7 22:17	45:20 46:5 49:3
13:11 21:3 38:17	11:21 12:3,10,18	27:13 32:10,14	22:21	50:11
40:4 42:19		-		
percentages 41:19	12:19 13:9,14,17	45:17,17 48:12	produce 13:12	proximity 20:18
perfectly 38:12	14:4 17:8,18,23	preemption 4:21	producers 41:3	public 12:24 16:16
periodiy 50.12	19:21 20:3 23:21	15:1 24:24,25	product 7:9 9:10	purchase 16:25
	l	l	l	

	I		I	I
pure 39:12	13:12	41:21 42:1 43:1	2:11 24:19,23,23	42:17,19 43:1
purely 21:8	read 40:16	43:12 44:6 46:24	25:6	47:2 51:3
purple 31:16,17	real 23:3 42:21	49:2 50:8	respondents 18:17	says 3:16 7:5,20
purport 45:8 49:1	reality 39:18	regulatory 5:10	response 39:6	12:11 13:13 17:8
purpose 6:10 12:24	realized 23:23	23:5 43:10	restriction 36:1	24:5 26:17 31:11
16:23 17:2	really 19:17 23:13	rejected 22:22	resurrect 45:2	33:5,15 39:5 41:1
purposes 9:8,11	30:17 42:23 43:4	relevant 27:10	review 36:6	41:9,25 48:2,16
29:8 34:17	reason 27:3 43:9	28:13 29:2 43:22	reviewed 43:2	51:9,10
pursuant 39:1	44:24	51:19	riegel 45:7	scalia 40:16 51:14
put 12:11,12 13:13	reasonable 24:11	relief 10:7	right 3:22 6:16 8:7	51:20
22:16 23:13 26:25	reasons 3:19 11:3	relies 24:23	8:12 15:25 21:24	scheme 27:17 32:11
28:7 30:2 34:19	15:8 23:15 43:7	religious 46:2	35:4,17,17 36:7	38:20
41:19	49:19	relying 29:9	43:2 49:4 51:22	scholar 51:11
putting 45:14	rebuttal 2:12 46:14	remainder 24:14	risk 11:25	scholarship 51:3
puzzles 16:17	recites 48:15	remaining 46:13	roberts 3:3 15:17	scope 37:14
	recognized 37:13	remand 15:9 17:21	20:19 21:7,19	second 19:17 24:12
Q	record 28:7 46:5	remedy 3:11	25:3 29:20 33:16	section 14:19 25:10
quality 14:12	red 33:19 39:22,22	remember 44:9	33:20 36:23 45:22	33:23,24 37:5
question 4:14,17	44:7,11	renders 33:7	46:9,12 52:1	sections 32:20 34:1
5:25 6:1,7,12,20	refer 46:1	repeatedly 35:16	romani 37:11	34:3
8:12 11:23 12:20	reference 43:23	46:21	rule 8:22 21:5	see 11:11,12 19:16
15:2,5 16:9 17:20	referring 46:19	reply 22:6 35:17,18	ruled 8:11	24:21 39:23 40:2
22:18 27:21 35:25	refers 37:6	represent 9:4,8	rulemaking 9:17	43:22 44:13
37:1 42:21 43:21	reg 35:16	representing 44:19	16:7 39:22 42:8	seek 10:7,12 39:21
47:16	regard 45:2	required 5:2,17 6:6	42:12 44:8 46:4	seeking 33:3
questions 15:15	regarding 45:12	6:14,22 10:19	47:12	seeks 36:14 39:2
quite 7:19 38:6	regime 43:10	32:20 37:9,12	rules 9:2 10:2	sell 3:14 37:19
40:6	register 9:5,14 34:5	requirement 13:23	18:21 42:14	sense 36:21 39:3
quote 11:25 25:11	47:7,20	30:9,10 41:21	run 36:1	serious 35:25
35:18	regulate 13:2	requirements 4:22	runs 11:24	served 16:17
quoting 47:20	regulating 30:8	4:24 5:2 25:11	<u> </u>	serving 29:8
R	regulation 5:7 7:22	41:3		set 22:20,20 29:5
$\frac{\mathbf{r}}{\mathbf{r}}$ 3:1	9:20 13:22 15:6	reserve 15:16	s 2:1 3:1 18:11 27:1	32:12 33:16,18,24
railroad 27:12,12	16:7,17 17:3	resolve 35:25	36:1 38:13 43:25	35:15
27:18	21:15 22:11 30:20	resolved 17:20	44:2,4	seth 1:15 2:3,13 3:7
raised 16:9 18:17	33:5,6 35:21	36:19,21	safety 12:25 14:20	46:14
45:16	44:15,16 47:8	resources 23:4	27:12,13,18 29:17 29:18,22,24 48:18	setting 22:14
rare 26:17	48:21 51:15,17	42:24 43:19 44:2	48:20 49:11	seven 46:13
rascranberry 41:17	regulations 3:18,21	respect 5:11 6:23	sanctions 13:2	seventh 27:14
42:11 43:11	4:7,8,10 6:3 8:4	11:20 17:21 18:13		sg 4:14,16
raspberryandcra	9:7 16:19 18:5,16	21:15,17 22:10	save 4:21	sherry 1:17 2:6
41:18	18:19 21:9 29:2	25:10 50:2,10	saying 7:13,18 10:14 13:7 19:9	15:18,19,22 16:19
reach 30:25	30:15,24 31:13,15	respectfully 44:3	19:24 21:16 22:19	17:15 18:2,6,10
reached 16:7	31:23 34:23,25	45:5	23:10 31:6 36:9	19:3,7,19 20:1,22
reaction 12:14	35:6 36:6,18,25	respond 42:21	38:8,9 39:7 41:16	21:13,24 22:12,24
	38:13,14 39:1	respondent 1:22	J0.0,7 J7.1 1 1.10	23:15 24:7,10
	l		l	l

40.10	01.500.0.500			1, , , , , , , , ,
49:10	21:5 22:3,15,22	strongly 47:12	supplanting 23:5	thats 4:13 5:19
shes 46:19	39:2 46:2 47:25	study 44:9,11 46:19	supplement 23:13	10:16 11:21 12:22
shifting 30:3	specificity 19:15	46:21	supplementing	14:13 17:12,20
shot 4:15	specify 10:11	stuff 13:18	23:4	18:8,10 24:4
shouldnt 11:4	spent 50:7	subject 4:10 14:25	supply 6:4 8:21	25:14,25 29:21
24:15	spoken 19:14	16:2 30:19	support 45:3	30:8,9,13,17,19
show 11:15	square 40:22	submission 5:5	supporting 1:19	33:3 35:7 36:1,3
showed 42:10	standard 16:3 22:8	50:13	2:8 15:21	38:6,23 42:7,14
shows 12:1 31:12	38:1 48:5	submitted 52:2,4	suppose 6:13 11:8	43:12 44:17 45:25
side 31:2 33:12	standardization	subsection 14:21	11:9 13:8 34:13	48:18 49:15
51:11	16:24	14:24	34:18 39:8,17,17	theories 11:3
simply 11:5,23 19:1	standards 4:5 30:4	subsections 16:21	39:19 42:9	theory 45:7,8
46:23 51:12	stands 28:11	subsequent 26:23	supposed 22:21	thereof 14:10 49:13
single 14:5 33:9	start 15:24	substantial 10:22	29:9	theres 4:17 28:15
sip 23:22	state 4:22,24 10:18	10:23 11:15,15,25	supreme 1:1,12	35:5 36:6 44:22
sixth 27:14	11:6 14:15,18,18	substantive 8:21	sure 17:10 21:24	45:25 46:6 51:5
size 31:7 32:17,18	15:4,11 24:25	10:2	27:21 51:7	thereunder 34:25
34:7	25:19,23,23 26:2	substitute 13:6	surprised 23:22	theyll 29:14
sizes 31:10	26:6,8,13,15,17	succumbed 28:5	24:3	theyre 49:5 50:13
slightly 19:8	27:6,8,13 32:10	sue 20:21 35:6	survey 39:9,10	theyve 19:11 48:24
small 9:15 12:6	32:13,14 34:15	49:20	swiss 48:11	thing 8:10 12:17
16:12	38:3,10 45:18	sufficient 43:19	symbols 14:9	18:14 40:2 42:8
solely 21:10	48:4,14,14	44:2		things 13:4 15:3
solicitor 1:17 7:5	statement 44:5,13	suggest 37:7 44:3	t2:1,1 5:3	23:10 42:22 44:25
solving 41:16	44:23 45:2,5	44:24 45:6	take 4:15 21:8 35:4	46:3
sorry 11:7 32:2	47:18	suggesting 12:8	35:8 42:24 44:18	think 6:13 8:24
sort 48:10	statements 47:19	suggestion 51:5	49:9 51:23	10:4 11:18 13:5
sorts 11:3,3	states 1:1,12,19 2:7	suggests 24:19	talk 20:4 22:14	13:20 14:17 17:16
sotomayor 4:4,13 17:10 18:2,7	3:20 15:9,20 36:2	suit 14:15 25:19 35:23 51:15,16	31:15	18:11 19:3,5,8
/	37:19 statute 5:5 6:9 8:22	suits 45:12,17	talking 13:21 23:3	20:10,11 22:24 23:3,25 24:2,7,8
28:23 30:6,12,22			23:5 24:13 29:23	, , , , , , , , , , , , , , , , , , ,
31:5,9,20 32:4,16 35:22 38:14 40:22	10:4 14:22 26:25 27:24 28:9 33:5	sullivan 1:21 2:10 4:16 25:4,5,7,25	29:25 32:5 49:20	24:10,10 28:8,12 28:13 30:17 31:6
40:25 41:22 42:3	34:2,16,17,22,24	26:16,21 27:5,9	tangerine 20:16	35:24 40:5,6
45:16	37:13,14 39:2	28:4,18 29:8,16	taste 17:11,14	42:10,18 43:20
sovereign 48:22	41:10 50:23	30:11,22 31:8,20	23:19	44:18 45:11 50:9
speak 21:25	statutes 9:9 16:2	32:6 33:8,18,21	tasted 23:21,23	51:22
speak 21.25 speaking 15:11	26:12 28:9 36:21	34:11,20 35:8,13	teaspoon 14:6	thinking 49:12,13
42:15	38:4 43:24	36:8,12 37:4,25	telling 14:3	thinks 29:14
specific 8:10 26:24	statutory 4:3 6:7	38:5,8,24 39:16	tendency 14:11	third 12:1
33:10 34:24,25	8:15 36:20 38:20	39:19 40:13,19,24	terms 21:22 25:1	thought 34:6,13,18
37:13 39:1,2	steroids 50:18	41:12 42:7,20	25:20	35:11,12 39:11
41:21 43:9,12	51:20	43:6,25 44:21	testimony 8:18	40:11
45:19 46:5,24	stick 42:2,4	45:4,11,14,23	thank 5:21 15:17	three 15:8
specifically 7:6	strawberry 12:21	46:10,18 48:2,16	25:3 46:9,11,16	threequarters
18:24 19:10,11	strip 3:21	49:4 51:9	47:22 51:25 52:1	44:12
10.2117.10,11	0011p 0.21	17.101.7		11.12
	I	1	I	1

threeyear 44:8,10	2:7 3:20 15:9,20	wanted 10:1 30:7	work 19:6,9 28:9	12761 1:4 3:4
46:18	36:2	37:17 41:25 50:24	works 28:10	15 2:8 17:24
thrust 43:20	unsupported 10:4	wants 32:21 35:15	world 42:21	17 35:18 39:23
time 15:16 26:25	unworkable 44:1	42:15	worried 48:17,17	18 39:23 40:1,3
30:1 35:19 50:8	upheld 42:5	warn 9:14	worry 29:19,20	1990 25:15 27:23
tincture 13:14	usc 33:13	warning 11:4 20:8	worse 41:8	1993 45:10
tiny 13:11	use 6:6,14,21,22	43:16	worth 11:21	1773 43.10
told 8:17 39:14	10:12 11:6 14:10	warnings 29:18,23	wouldnt 13:25 14:1	2
total 14:4	30:14,15,16 31:18	warrant 14:8	15:2,11 23:8,11	2 29:22 33:13,23
touched 19:24	40:4	washington 1:8,15	48:4,5	34:10
touched 19.24 touchstone 37:9	uses 8:22 39:25	1:18	write 38:19	2014 1:9
tremendous 42:22	usual 16:11,23 22:2	wasnt 42:12 48:17	writing 49:2	21 1:9 33:13 39:24
true 12:8 41:14	36:20	washt 42.12 48.17 waxman 1:15 2:3	wrung 49.2 wrong 7:14	23 22:6
try 18:10 19:7	utterly 34:14	2:13 3:6,7,9 4:12	wyeth 5:12 6:2,2,17	25 2:11 16:8
trying 4:14 20:12	utterly 54.14	4:15 5:18,21 6:1	11:2 40:23,25	2900 47:20
36:13 47:3	\mathbf{V}	6:17 7:16,21 8:5	41:7,11,22 42:2	2919 9:13 47:21
twice 9:17	v 1:5 3:4 4:20	8:12 10:10,16	+1./,11,22 42.2	2920 9:13 47:21
twice 9:17 two 7:1 11:22 16:1	valid 39:10	11:11 12:16 13:20	X	
23:15 29:7 31:10	vast 13:15,20	14:17 33:2 39:14	x 1:2,7	3
31:22 34:1 38:4	verba 14:21 48:15	42:15 43:13 45:6		3 2:4 17:18 33:13
38:16 41:12 43:24	verdict 39:7	46:12,14,16 47:19	Y	33:24
47:2	vermont 11:6	47:23 49:9,18	yeah 7:17 40:19	33 16:6 39:24
type 9:20 19:12	versus 7:20 11:2	51:4,18,22	years 16:8	337 36:1 45:15 46:6
31:25 32:2,20	victims 6:10	waxmans 28:5	york 1:21,21	341 25:10 37:5
31.23 32.2,20	view 17:24 22:13	way 14:3 22:19	youll 39:23 44:12	343 14:22 16:20
U	49:11	28:10 30:16,19	youre 7:12,18	21:25 34:3,3,4,4,7
u 27:1 38:13 43:25	views 49:10	44:12 49:6	19:17 30:14,18	34:9,10 44:14,15
44:2,4	vignette 31:12	ways 38:16	38:2 50:19	45:21 48:8,15
ultimately 21:6	32:17,18 34:4,5	welfare 49:12	youve 13:13 23:8	50:16
30:4	45:24	wellbeing 21:11	37:11,12	3431 33:13
unbroken 27:10	vignettes 31:14	went 7:6		39 35:12
undermine 31:3	violated 11:5	weren 5:3	Z	
undermined 27:19	violates 4:7	weve 6:20 9:5 15:7	0	4
understand 6:19	violation 3:14,22	24:12 28:7	$\frac{0}{0.17:18}$	4 12:22
8:7 14:8 17:7	35:5	whats 14:2 48:18	01 7.18 01 12:21	46 2:14
18:23 21:20 23:8	virtue 18:16	whatsoever 48:13	06 1:13 3:2	5
understanding	volume 17:6	50:22 51:6	00 1.13 3.2 07 52:3	5 24:20
24:18 49:14		whos 49:21	07 32.3	50 11:9 37:19
understood 36:4	W	willful 3:22 10:24	1	58 9:14 47:19,20
uniform 32:11	walk 42:16	win 34:20	1 21:25 50:16	5a 33:19,24
33:23 41:25	want 5:24 12:23	wonderful 1:3 3:4	10 17:23	3a 33.17,24
uniformity 27:18	13:17 23:17 28:21	wont 33:25 40:5	100 20:18	6
27:23 28:2 31:4	32:23 33:4,11	word 39:25	102 16:6 39:24	6 29:22
37:18,21 39:3	34:12 38:18,18,23	words 8:23 14:9	11 1:13 3:2	6a 33:24
unintelligent 40:6	38:25 40:1 43:10	16:3 20:2,5,15,16	110660 14:19	
united 1:1,12,19	43:22	20:24	12 52:3	7
L				

7 20:9 39:5 44:7,11			Page 63
8 99 12:22 13:8	7 20:9 39:5 44:7,11		
9 99 12:22 13:8			
99 12:22 13:8			
999 13:8	99 12:22 13:8		
	999 13:8		
· · · · · · · · · · · · · · · · · · ·			